10 October 2022
EMA/CHMP/770559/2022
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Draft agenda for the meeting on 10-13 October 2022

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

10 October 2022, 09:00 – 19:30, virtual meeting/room 1C

11 October 2022, 08:30 – 19:30, virtual meeting/room 1C

12 October 2022, 08:30 – 19:30, virtual meeting/room 1C

13 October 2022, 08:30 – 15:00, virtual meeting/room 1C

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged.

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 10-13 October 2022. See October 2022 CHMP minutes (to be published post November 2022 CHMP meeting).

1.2. Adoption of agenda

CHMP agenda for 10-13 October 2022.

1.3. Adoption of the minutes

CHMP minutes for 12-15 September 2022.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 03 October 2022.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. iodine (131I) omburtamab - Orphan - EMEA/H/C/005499

Y-Mabs Therapeutics A/S; treatment of neuroblastoma

Scope: Possible oral explanation

Action: Possible oral explanation to be held on 11 October 2022 at 14:00

List of Outstanding Issues adopted on 23.06.2022. List of Questions adopted on 16.09.2021.

2.1.2. lutetium (177Lu) vipivotide tetraxetan - EMEA/H/C/005483

treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)

Scope: Oral explanation

Action: Oral explanation to be held on 12 October 2022 at 16:00

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on 24.02.2022.

2.1.3. spesolimab - EMEA/H/C/005874

treatment of flares in adult patients with generalised pustular psoriasis

Scope: Oral explanation

Action: Oral explanation to be held on 11 October 2022 at 16:00

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on 24.02.2022.

2.2. Re-examination procedure oral explanations

No items

2.3. Post-authorisation procedure oral explanations

2.3.1. Libtayo - cemiplimab - EMEA/H/C/004844/II/0026

Regeneron Ireland Designated Activity Company (DAC)

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include monotherapy treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy for Libtayo; sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3 of the RMP has also been submitted."

Oral explanation

Action: Oral explanation to be held on 12 October 2022 at 11:00

Request for Supplementary Information adopted on 23.06.2022, 24.02.2022.

See 5.1

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. dengue tetravalent vaccine (live, attenuated) - Article 58 - EMEA/H/W/005362

prevention of dengue disease

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 23.06.2022, 11.11.2021. List of Questions adopted

on 24.06.2021.

3.1.2. dimethyl fumarate - EMEA/H/C/005963

treatment of multiple sclerosis

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 21.07.2022, 22.04.2022. List of Questions adopted on 27.01.2022.

3.1.3. tabelecleucel - PRIME - Orphan - ATMP - EMEA/H/C/004577

Atara Biotherapeutics Ireland Limited; treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV^+ PTLD)

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 09.09.2022. List of Questions adopted on 18.03.2022.

3.1.4. abaloparatide - EMEA/H/C/005928

treatment of osteoporosis

Scope: Opinion

Action: For adoption

List of Questions adopted on 24.03.2022.

3.1.5. maralixibat - Orphan - EMEA/H/C/005857

Mirum Pharmaceuticals International B.V.; Treatment of cholestatic liver disease in patients with Alagille syndrome (ALGS) 1 year of age and older

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.09.2022, 23.06.2022. List of Questions adopted on 27.01.2022.

3.1.6. gozetotide - EMEA/H/C/005488

indicated for the identification of prostate-specific membrane antigen (PSMA)-positive lesions after radiolabelling with gallium-68

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on

24.02.2022.

3.1.7. pemetrexed - EMEA/H/C/005848

treatment of malignant pleural mesothelioma and non-small cell lung cancer

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 15.09.2022, 19.05.2022. List of Questions adopted on 16.12.2021.

3.1.8. plerixafor - EMEA/H/C/005943

treatment of lymphoma and multiple myeloma

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on 24.02.2022.

3.1.9. dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/005155

prevention of dengue disease

Scope: Opinion

Action: For adoption

List of Outstanding Issues adopted on 23.06.2022, 11.11.2021. List of Questions adopted on 24.06.2021.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. dimethyl fumarate - EMEA/H/C/005950

treatment of multiple sclerosis

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 22.04.2022.

3.2.2. pegfilgrastim - EMEA/H/C/005810

Treatment of neutropenia

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 27.01.2022.

3.2.3. etranacogene dezaparvovec - PRIME - Orphan - ATMP - EMEA/H/C/004827

CSL Behring GmbH; treatment of adults with Haemophilia B

Scope: List of outstanding issues

Action: For information

List of Questions adopted on 15.07.2022.

3.2.4. tremelimumab - EMEA/H/C/004650

treatment of adults with metastatic NSCLC with no sensitising epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumour aberrations

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 22.04.2022.

3.2.5. paclitaxel - EMEA/H/C/005997

treatment of metastatic breast cancer

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 19.05.2022.

3.2.6. sodium thiosulfate - PUMA - EMEA/H/C/005130

for the prevention of ototoxicity induced by cisplatin (CIS) chemotherapy in patients 1 month to < 18 years of age with localized, non-metastatic, solid tumours.

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 16.12.2021, 24.06.2021. List of Questions adopted on 25.06.2020.

3.2.7. ruxolitinib - EMEA/H/C/005843

treatment of non-segmental vitiligo

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.02.2022.

3.2.8. tolvaptan - EMEA/H/C/005961

treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 22.04.2022.

3.2.9. SARS-CoV-2 prefusion Spike delta TM protein, recombinant - EMEA/H/C/005754

Active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 20.06.2022.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. aripiprazole - EMEA/H/C/005929

Maintenance treatment of schizophrenia

Scope: List of questions

Action: For adoption

3.3.2. crisantaspase - EMEA/H/C/005917

Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL).

Scope: List of questions

Action: For adoption

3.3.3. pirtobrutinib - Orphan - EMEA/H/C/005863

Eli Lilly Nederland B.V.; treatment of mantle cell lymphoma (MCL)

Scope: List of questions

Action: For adoption

3.3.4. treprostinil diolamine - Orphan - EMEA/H/C/005990

Ferrer Internacional S.A.; Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity.

The studies that established effectiveness included predominantly patients with WHO functional class II-III symptoms and aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease (see section 5.1).

Scope: List of questions

Action: For adoption

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. molnupiravir - EMEA/H/C/005789

Treatment of coronavirus disease 2019 (COVID-19)

Scope: Update on the status of the procedure

Action: For information

List of Outstanding Issues adopted on 22.04.2022, 24.02.2022. List of Questions adopted on 16.12.2021.

3.4.2. dabigatran etexilate - EMEA/H/C/005922

prevention of venous thromboembolic events

Scope: Letter by the applicant dated 26.09.2022 requesting an extension to the clock stop to respond to the list of questions adopted in June 2022.

Action: For adoption

List of Questions adopted on 23.06.2022.

3.4.3. vadadustat - EMEA/H/C/005131

Treatment of anaemia

Scope: Request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in September 2022.

Action: For information

List of Outstanding Issues adopted on 15.09.2022. List of Questions adopted on 24.03.2022.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in September 2022 at its PROM meeting held on 03.10.2022.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

No items

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

No items

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Comirnaty - tozinameran - EMEA/H/C/005735/X/0138

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson

Scope: "Extension application to add a new strength of 3 µg for individuals 6 months to 4 years of age. In addition, the applicant took the opportunity to introduce editorial changes in Annex I, IIIA and IIIB of the PI. The RMP (version 5.1) is updated in accordance."

Action: For adoption

4.1.2. Refixia - nonacog beta pegol - EMEA/H/C/004178/X/0027/G

Novo Nordisk A/S

Rapporteur: Andrea Laslop

Scope: "Extension application to introduce a new strength (3000 IU Powder and solvent for solution for injection). The extension application is grouped with a type II variation (B.II.d.1.e).

Sections 1, 2, 5.3, 6.3, 6.6 and 8 of the SmPC, the Labelling and Package Leaflet are updated."

Action: For adoption

List of Questions adopted on 21.07.2022.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Adcirca - tadalafil - EMEA/H/C/001021/X/0035/G

Eli Lilly Nederland B.V.

Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (2 mg/ml oral suspension) grouped with a type II variation (C.I.6.a) to include paediatric use (from 6 months to 17 years) based on study 4 (H6D-MC-LVHV [LVHV]) - A 24-week placebo-controlled efficacy and safety study with an open-label long-term extension phase. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The paediatric indication is applicable to the new and all existing presentations. The Package Leaflet and Labelling are updated accordingly. Furthermore, the PI is brought in line with the latest QRD template and editorial changes have been implemented. The RMP (version 9.1) is updated in accordance."

Action: For adoption

List of Questions adopted on 19.05.2022.

4.2.2. Ultomiris - ravulizumab - EMEA/H/C/004954/X/0027/G

Alexion Europe SAS

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension application to introduce a new pharmaceutical form (solution for injection) associated with new strength (245 mg) and route of administration (subcutaneous use), grouped with a type II variation (C.I.4) to align the Summary of product characteristics and Labelling of Ultomiris intravenous formulation (IV) with the proposed Ultomiris subcutaneous formulation (SC).
The RMP (version 5.0) is updated in accordance."

Action: For adoption

List of Questions adopted on 21.07.2022.

4.2.3. Triumeq - dolutegravir / abacavir / lamivudine - EMEA/H/C/002754/X/0101/G

ViiV Healthcare B.V.

Rapporteur: Filip Josephson, PRAC Rapporteur: Martin Huber

Scope: "Extension application to introduce a new pharmaceutical form associated with new strength (5 mg/60 mg/30 mg dispersible tablet). The new presentation is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected children weighing at least 14 kg to less than 25 kg.
This extension application is grouped with a type II variation (C.I.6.a) to include treatment of children weighing at least 25 kg for the already approved film-coated tablets for Triumeq (EU/1/14/940/001-002); as a consequence, sections 4.1, 4.2, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance.
The RMP (version 19) is updated in accordance."

Action: For adoption

List of Questions adopted on 19.05.2022.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Hefiya - adalimumab - EMEA/H/C/004865/X/0036/G

Sandoz GmbH

Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to add a new strength (80 mg/0.8 ml) of the solution for injection grouped with quality variations. The Package Leaflet and Labelling are updated in accordance.
The RMP (version 9.0) has also been submitted.
Additionally, the applicant takes the opportunity to include editorial changes in the pack sizes (approved (001-003) and new presentations) in the List of All Authorised Presentations (Annex A) to differentiate packs of pre-filled syringes with or without needle safety device."

Action: For adoption

4.3.2. Hyrimoz - adalimumab - EMEA/H/C/004320/X/0036/G

Sandoz GmbH

Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to add a new strength (80 mg/0.8 ml) of the solution for injection grouped with quality variations. The Package Leaflet and Labelling are updated in accordance.
The RMP (version 9.0) has also been submitted.
Additionally, the applicant takes the opportunity to include editorial changes in the pack sizes (approved (001-003) and new presentations) in the List of All Authorised Presentations (Annex A) to differentiate packs of pre-filled syringes with or without needle safety device."

Action: For adoption

4.3.3. Orkambi - lumacaftor / ivacaftor - EMEA/H/C/003954/X/0078/G

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Armando Genazzani, Co-Rapporteur: Finbarr Leacy, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension application to add a new strength of 75 mg of lumacaftor and 94 mg of ivacaftor fixed dose combination granules, grouped with a type II variation (C.I.6.a).
C.I.6: Extension of indication to include treatment of cystic fibrosis for children aged 1 to less than 2 years old of age who are homozygous for the F508del mutation in the CFTR gene, based on final results from study 122, a 2-part study of CF subjects 1 to <2 years of age homozygous for F508del. As a consequence, sections 4.1, 4.2, 4.5, 4.6, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 11.2 of the RMP has also been submitted."

Action: For adoption

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

4.4.1. Betmiga - mirabegron - EMEA/H/C/002388/X/0039/G

Astellas Pharma Europe B.V.

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon

Scope: Letter by the applicant dated 22.09.2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in September 2022.

Action: For adoption

List of Outstanding Issues adopted on 15.09.2022. List of Questions adopted on 22.04.2022.

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Brukinsa - zanubrutinib - EMEA/H/C/004978/II/0003

BeiGene Ireland Ltd

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) based on results from study BGB-3111-304; an ongoing, international, Phase 3, open-label, multiple-cohort, randomized study designed to evaluate the efficacy of zanubrutinib versus B+R in patients with previously untreated CLL/SLL, and study BGB-3111-305; an ongoing, international Phase 3, open-label, randomized study of zanubrutinib versus ibrutinib with R/R CLL/SLL. As a consequence, sections 4.1, 4.2, 4.4, 4,5, 4.6, 4.8, 5.1 and 5.2 of the SmPC are being updated. The Package Leaflet is updated in accordance. An updated RMP version 1.1 (specific for the proposed indication CLL/SLL) was also submitted. In addition, as part of the application the MAH requested a 1-year extension of the market protection."

Action: For adoption

Request for Supplementary Information adopted on 19.05.2022.

5.1.2. Dupixent - dupilumab - EMEA/H/C/004390/II/0060

sanofi-aventis groupe

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Finbarr Leacy, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of atopic dermatitis in paediatric patients from 6 months to <6 years of age based on final results from study R668-AD-1539; this is a phase 2/3 study investigating the pharmacokinetics, safety and efficacy of dupilumab in patients aged ≥6 months to <6 years with moderate-to-severe atopic dermatitis. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 23.06.2022.

5.1.3. Esbriet - pirfenidone - EMEA/H/C/002154/II/0074

Roche Registration GmbH

Rapporteur: Finbarr Leacy, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension of indication to include treatment of 'advanced' idiopathic pulmonary fibrosis (IPF) by the deletion of the current qualifier 'mild to moderate', based on the results from study MA29957; this is a 52-week Phase IIb, multicentre, randomised, double-blind, placebo-controlled clinical trial in IPF patients with advanced lung function impairment (DLco < 40% of predicted) and at high risk of grade 3 pulmonary hypertension, and additional analyses performed on the original pivotal trials for pirfenidone in IPF.
As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. In addition, the MAH took the opportunity to include information in section 4.4 of the SmPC related to the content of sodium per Esbriet capsule and tablet. The Package Leaflet is updated in accordance. Version 12.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 19.05.2022.

5.1.4. Evrysdi - risdiplam - Orphan - EMEA/H/C/005145/II/0005/G

Roche Registration GmbH

Rapporteur: Bruno Sepodes, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Jan Neuhauser

Scope: "Grouping of three variations as follows:
Extension of indication to include treatment of patients below 2 months of age based on interim results from study BN40703 (RAINBOWFISH). The pivotal study RAINBOWFISH is

an ongoing phase II multicentre, open-label, and single-arm study designed to evaluate the efficacy, safety, tolerability, and PK/PD of risdiplam in pre-symptomatic infants below 2 months of age who were genetically diagnosed with SMA. As a consequence, SmPC sections 4.1, 4.2, 4.8, 5.1 and 5.2 have been updated and the Package Leaflet has been updated in accordance. In addition, the MAH took the opportunity to make some editorial improvements in the product information. A revised RMP version 1.1 was also submitted as part of the application.
Type IAIN, B.IV.1.a.1 variation to update Evrysdi pack configuration with the addition of a new 1 mL oral syringe into the product carton allowing precise dosing of infants below 2 months of age. As a consequence, section 6.5 of the SmPC has been updated and the labelling and Package Leaflet have been updated in accordance.
Type IAIN, B.IV.1.b variation to remove the spare unit of 12 mL oral syringe out of the two units currently provided in the product carton. As a consequence, section 6.5 of the SmPC has been updated and the labelling and Package Leaflet have been updated in accordance."

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022, 22.04.2022.

5.1.5. Eylea - aflibercept - EMEA/H/C/002392/II/0077/G

Bayer AG

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Nathalie Gault

Scope: "C.I.6 (Extension of indication) Extension of indication to include the paediatric indication retinopathy of prematurity (ROP) for Eylea; as a consequence, sections 2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Separate Package Leaflet is proposed for the guardians of preterm babies. Version 32.1 of the RMP has also been submitted. B.IV.1.a.3."

Action: For adoption

Request for Supplementary Information adopted on 24.02.2022.

5.1.6. Fintepla - fenfluramine - Orphan - EMEA/H/C/003933/II/0012

Zogenix ROI Limited

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication to include treatment of seizures associated with Lennox-Gastaut syndrome as an add on therapy to other anti-epileptic medicines for patients 2 years of age and older. As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.3 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022.

5.1.7. Hemlibra - emicizumab - EMEA/H/C/004406/II/0027

Roche Registration GmbH

Rapporteur: Alexandre Moreau, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension of indication to include treatment of adult and paediatric patients with haemophilia A without factor VIII (FVIII) inhibitors who have mild or moderate disease for whom prophylaxis is clinically indicated. Consequently, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC and section 1 of the package leaflet are updated. In addition, section 4.2 is updated to make it clear that the maintenance dose for Hemlibra applies from week 5 of dosing. The PIL is updated accordingly. Version 4.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 19.05.2022, 27.01.2022.

5.1.8. Imbruvica - ibrutinib - EMEA/H/C/003791/II/0073

Janssen-Cilag International N.V.

Rapporteur: Filip Josephson, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension of indication to include treatment with Imbruvica in combination with bendamustine and rituximab (BR) of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for autologous stem cell transplantation, based on final results from the category 3 study PCI-32765MCL3002 (SHINE); this is a randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with BR in subjects with newly diagnosed MCL. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 19.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 23.06.2022.

5.1.9. Imfinzi - durvalumab - EMEA/H/C/004771/II/0041

AstraZeneca AB

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: David Olsen

Scope: "Extension of indication to include first-line treatment, with Imfinzi in combination with tremelimumab and platinum-based chemotherapy, of adults with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumour aberrations, based on final results from study D419MC00004 (POSEIDON); This was a Phase III, randomised, multicentre, open-label, comparative global study to determine the efficacy and safety of tremelimumab and durvalumab or durvalumab in combination with platinum based chemotherapy for first-line treatment in patients with metastatic NSCLC. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.2. Version 5.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022.

5.1.10. Imfinzi - durvalumab - EMEA/H/C/004771/II/0046

AstraZeneca AB

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: David Olsen

Scope: "Extension of indication to include Imfinzi in combination with chemotherapy for the treatment of adults with locally advanced or metastatic biliary tract cancer (BTC), based on the second interim analysis from the ongoing pivotal study D933AC00001 (TOPAZ-1); a phase III randomized, double-blind, placebo-controlled, multi-regional, international study conducted to assess the efficacy and safety of durvalumab in combination with the current standard of care Gemcitabine/Cisplatin for the first-line treatment of patients with locally advanced or metastatic BTC. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated and the Package Leaflet has been updated accordingly. Version 7.1 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022.

5.1.11. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0121

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include Keytruda as monotherapy for the adjuvant treatment of adults with Stage IB (T2a ≥ 4 cm), II or IIIA non-small cell lung carcinoma (NSCLC) who have undergone complete resection, based on study KEYNOTE-091; an ongoing Phase 3, randomized, triple-blinded, placebo-controlled, multicenter study of pembrolizumab versus placebo in patients with early-stage NSCLC after resection and completion of standard adjuvant therapy. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are being updated and the Package Leaflet is updated in accordance. An updated RMP version 39.1 was also submitted."

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022.

5.1.12. Libtayo - cemiplimab - EMEA/H/C/004844/II/0026

Regeneron Ireland Designated Activity Company (DAC)

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include monotherapy treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy for Libtayo; sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 23.06.2022, 24.02.2022.

See 2.3

5.1.13. Lynparza - olaparib - EMEA/H/C/003726/II/0053

AstraZeneca AB

Rapporteur: Alexandre Moreau, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension of indication to include treatment of adults with metastatic castration resistant prostate cancer (mCRPC), with Lynparza in combination with abiraterone and prednisone or prednisolone, based on the results of the pivotal Phase III study PROpel (D081SC00001) and supportive evidence from study 8 (D081DC00008). PROpel is a Phase III, randomised, double-blind, placebo-controlled, multicentre study evaluating olaparib vs placebo in combination with abiraterone as first line treatment for men with mCRPC. Consequently, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC for Lynparza tablets are being updated. In addition, sections 4.4 and 4.8 of the SmPC for Lynparza hard capsules are revised based on the updated safety data analysis. The Package Leaflet is updated accordingly. The RMP version 24 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022, 22.04.2022.

5.1.14. Lyumjev - insulin lispro - EMEA/H/C/005037/II/0014

Eli Lilly Nederland B.V.

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Mari Thorn

Scope: "Extension of indication to include the treatment of diabetes mellitus in adolescents and children aged 1 year and above, based on final results from study I8B-MC-ITSB; this is a pivotal Phase 3 study designed to evaluate the safety and efficacy of Lyumjev compared to Humalog in combination with basal insulin in children and adolescent patients with T1D. The study was designed to compare change in HbA1c as the primary endpoint. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial and linguistic changes in the SmPC and Package Leaflet.
As part of the application, the MAH is also requesting one additional year of market protection."

Action: For adoption

Request for Supplementary Information adopted on 15.09.2022, 21.07.2022, 22.04.2022.

5.1.15. Opdivo - nivolumab - EMEA/H/C/003985/II/0117

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include Opdivo in combination with platinum-based chemotherapy for neoadjuvant treatment of adult patients with resectable Stage IB-IIIA

non-small cell lung cancer (NSCLC), based on results from study CA209816; a randomised, open-label, phase 3 trial of nivolumab plus ipilimumab or nivolumab plus platinum-doublet chemotherapy versus platinum-doublet chemotherapy in early-stage NSCLC. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 27.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 23.06.2022.

5.1.16. Ronapreve - casirivimab / imdevimab - EMEA/H/C/005814/II/0002

Roche Registration GmbH

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include treatment of COVID-19 in hospitalised patients in adults and adolescents aged 12 years and older weighing at least 40 kg for Ronapreve; as a consequence, sections 4.2, 4.4, 4.8, 4.9, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 1.1 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 19.05.2022.

5.1.17. Spikevax - elasomeran - EMEA/H/C/005791/II/0067

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: "Extension of indication to include immunisation of paediatric individuals from 6 months through 5 years of age based on results from the study P204 (KidCove); this is a phase 2/3, two-part, open-label, dose-escalation, age de-escalation and randomized, observer-blind, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273 SARS-CoV-2 vaccine in healthy children 6 months to less than 12 years of age. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated and the Package Leaflet is updated in accordance. The MAH also took the opportunity to implement minor editorial changes in the product information. The submission includes a revised RMP version 4.1."

Action: For adoption

Request for Supplementary Information adopted on 23.06.2022.

5.1.18. Trulicity - dulaglutide - EMEA/H/C/002825/II/0065

Eli Lilly Nederland B.V.

Rapporteur: Martina Weise, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Amelia Cupelli

Scope: "Extension of indication to include treatment of type 2 diabetes mellitus (T2DM) in children and adolescents aged 10 to less than 18 years based on final results from study H9X-MC-GBGC; this is a phase 3, double-blind, randomised, multi-centre, placebo-controlled superiority trial to evaluate PK, PD, safety and efficacy of dulaglutide in children from 10 to less than 18 years of age, with an open label extension to evaluate safety. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7.1 of the RMP has also been submitted."

Action: For adoption

5.1.19. Xydalba - dalbavancin - EMEA/H/C/002840/II/0043

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Filip Josephson, PRAC Rapporteur: Rugile Pilviniene

Scope: "Extension of indication to the paediatric population (aged 3 months to < 18 years) for the treatment of ABSSSI based on the interim results from the safety and efficacy Phase 3 study DUR001-306, together with data from 3 Phase 1 PK studies (A8841004, DUR001-106 and DAL-PK-02). Consequently, the sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC were updated. The Package Leaflet has been updated accordingly.
In addition, the applicant has taken the opportunity to make minor editorial amendments and QRD updates (v10.2) to the SmPC/PIL. Version 7.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 23.06.2022.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.2.1. Gavreto - pralsetinib - EMEA/H/C/005413/II/0002/G

Roche Registration GmbH

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ulla Wändel Liminga

Scope: Letter by the applicant dated 22.09.2022 requesting an extension to the clock stop to respond to the request for supplementary information adopted in September 2022.

Action: For adoption

Request for Supplementary Information adopted on 15.09.2022, 23.06.2022, 24.03.2022.

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

6.1.1. gentamicin sulfate / sargramostim / heparin sodium / insulin human - EMEA/H/D/006090

human assisted reproductive techniques including in-vitro fertilisation procedures

Scope: Day 120 list of questions

Action: For adoption

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics - initial consultation

6.3.1. in vitro diagnostic medical device - EMEA/H/D/006107

In vitro qualitative immunohistochemical detection of programmed death-ligand 1 (PD-L1)

Scope: Opinion

Action: For adoption

6.4. Companion diagnostics – follow-up consultation

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Evusheld - tixagevimab / cilgavimab - EMEA/H/C/005788/II/0003

AstraZeneca AB

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kimmo Jaakkola

"Update of sections 4.2, 4.8, 4.9, 5.1 and 5.2 of the SmPC in order to change the posology recommendations in the pre-exposure prophylaxis indication based on study TACKLE (D8851C00001). The Package Leaflet is updated accordingly. The RMP version 2 has also been submitted."

Action: For adoption

9.1.2. Spikevax - elasomeran - EMEA/H/C/005791/II/84/G

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus

Scope: "B.I.a.6.a (Type II): Addition of a new strain (Omicron BA.4-5) resulting in a new Spikevax bivalent Original/Omicron BA.4-5 (50 µg elasomeran/50 µg davesomeran)/mL 0.1 mg/mL dispersion for injection presentation. The Annex A, the SmPC, the Annex II, the labelling and the Package Leaflet are updated accordingly."

Action: For adoption

9.1.3. Ronapreve - casirivimab / imdevimab - EMEA/H/C/005814/II/0007

Roche Registration GmbH

Rapporteur: Jan Mueller-Berghaus

Scope: "Update of sections 4.2, 4.4, 5.1 and 5.2 of the SmPC in order to introduce the proposed dose for SARS-CoV-2 Omicron BA.2, BA.2.12.1, BA.4, and BA.5 subvariants along with dose preparation and infusion instructions for treatment of outpatients and post-exposure prophylaxis as well as to update efficacy and pharmacokinetic information based on pharmacokinetic (PK) modelling data from R10933-PK-21187-SR-01V2 and R10933-R10987-4800mgIV-KRM and in vitro viral neutralisation data from the updated virus neutralisation report R10933-PH-20091-SR-01V7 and its addendum; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Action: For adoption

9.1.4. Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/R/0079

AstraZeneca AB

Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné

Scope: Renewal of conditional marketing authorisation; proposal to switch to standard marketing authorisation

Action: For adoption

9.1.5. Natpar - Parathyroid hormone – EMEA/H/C/003861

Takeda Pharmaceuticals International AG

Rapporteur: Karin Janssen van Doorn, Co-Rapporteur: Agnes Gyurasics

Scope: DHPC; the DHPC has been adopted via written procedure on 26 September 2022.

Action: For information

9.1.6. Comirnaty - tozinameran - EMEA/H/C/005735/II/0139

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson

Scope: "Update of sections 4.8 and 5.1 of the SmPC of Comirnaty 30 µg concentrate for dispersion for injection and Comirnaty 30 µg dispersion for injection as well as section 4.8 of the SmPC of Comirnaty 10 µg concentrate for dispersion for injection in order to update information based on six-month post (booster) dose three interim report data in patients aged 16 years of age and above from studies C4591001 and C4591031. Study C4591001 is a phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals, while study C4591031 is a phase 3 master protocol to evaluate additional dose(s) of BNT162b2 in healthy individuals previously

vaccinated with BNT162b2."

Action: For adoption

9.1.7. WS2244 - Nuwiq-EMEA/H/C/002813/WS2244/0048 Vihuma-EMEA/H/C/004459/WS2244/0030

Octapharma AB

Lead Rapporteur: Jan Mueller-Berghaus

Scope: "Update of sections 4.8 and 5.1 of the SmPC in order to add safety and efficacy data based on the final CSR from the category 3 study GENA-21b; a prospective, open-label, multicentre phase 3b study to assess the efficacy and safety of personalized prophylaxis with Human-cl rhFVIII in previously treated adult patients with severe haemophilia A. Further, upon request by the CHMP following the assessment of study GENA-05 (P46 013 and P46 014), the MAH is updating the numbers of evaluated subjects in SmPC section 4.8 and is removing of the sentence "A prospective open-label clinical study in PUPs with severe haemophilia A (<1% FVIII:C) is ongoing" in section 5.1 of the SmPC. The Package Leaflet is updated accordingly."

Action: For adoption

Request for Supplementary Information adopted on 01.09.2022, 16.06.2022, 05.05.2022.

9.1.8. Imbruvica - ibrutinib - EMEA/H/C/003791/II/0075

Janssen-Cilag International N.V.,

Rapporteur: Filip Josephson

Scope: "Update of section 4.2 of the SmPC to incorporate information specific for dose modifications for non-cardiac events and events of cardiac failure or cardiac arrhythmias events based on data pool from clinical studies which included 4 Phase II (PCYC-1102-CA, PCYC-1104-CA, PCYC-1118E, PCYC-1142-CA) and 8 Phase III studies (PCYC-1112-CA, PCYC-1115-CA, CLL3001, PCYC-1130-CA, MCL3001, PCYC-1127-CA, CLL3011, and MCL3002)."

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

No items

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

No items

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

October 2022 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. Vote by proxy

None

14.1.2. CHMP membership

None

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for October 2022

Action: For adoption

14.2.2. Paediatric Committee (PDCO)

PIPs reaching D30 at October 2022 PDCO

Action: For information

Report from the PDCO meeting held on 26-29 September 2022

Action: For information

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/Sean Barry

Reports from BWP October 2022 meeting to CHMP for adoption:

- 13 reports on products in scientific advice and protocol assistance
- 10 reports on products in pre-authorisation procedures

- 1 report on products in post-authorisation procedures
- 3 reports on products in plasma master file

Action: For adoption

14.3.2. Name Review Group (NRG)

Table of Decisions of the NRG meeting held on 20-21 September 2022.

Action: For adoption

14.3.3. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

Report from the SAWP meeting held on 26-29 September 2022. Table of conclusions

Action: For information

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.4. Vice-Chair election of the Central Nervous System Working Party (CNSWP)

Election of vice-chair of the Central Nervous System Working Party.

Application(s) received

Action: For adoption

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

No items

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

15.1.2. Regulatory & scientific conference on RNA based medicines

This conference aims to facilitate the dialogue between industry/academia and regulators, to discuss scientific and regulatory opportunities and challenges to promote the development of RNA-based innovative medicines

Action: For information

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

10 October 2022
EMA/CHMP/770646/2022

Annex to 10-13 October 2022 CHMP Agenda

Pre-submission and post-authorisations issues

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged.

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for October 2022: **For adoption**

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for October 2022: **For adoption**

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Bylvay - odevixibat - EMEA/H/C/004691/S/0008, Orphan
Albireo, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski

MVABEA - ebola vaccine (rDNA, replication-incompetent) - EMEA/H/C/005343/S/0015
Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jean-Michel Dogné

Qarziba - dinutuximab beta - EMEA/H/C/003918/S/0046, Orphan
EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski

ZABDENO - ebola vaccine (rDNA, replication-incompetent) - EMEA/H/C/005337/S/0012
Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur:

Jean-Michel Dogné

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

Zessly - infliximab -
EMEA/H/C/004647/R/0025
Sandoz GmbH, Rapporteur: Eva Skovlund, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Ulla Wändel Liminga

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Lamzede - velmanase alfa -
EMEA/H/C/003922/R/0029, Orphan
Chiesi Farmaceutici S.p.A., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Jan Neuhauser

Lokelma - sodium zirconium cyclosilicate -
EMEA/H/C/004029/R/0027
AstraZeneca AB, Rapporteur: Silvijus Abramavicius, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Kirsti Villikka

Riarify - beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium -
EMEA/H/C/004836/R/0022
Chiesi Farmaceutici S.p.A., Informed Consent of Trimbow, Rapporteur: Janet Koenig, Co-Rapporteur: Finbarr Leacy, PRAC Rapporteur: Jan Neuhauser

Semglee - insulin glargine -
EMEA/H/C/004280/R/0040
Viatris Limited, Rapporteur: Martina Weise, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Menno van der Elst

Shingrix - herpes zoster vaccine (recombinant, adjuvanted) -
EMEA/H/C/004336/R/0057
GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Sonja Hrabcik

Trydonis - beclometasone dipropionate / formoterol fumarate dihydrate /

glycopyrronium - EMEA/H/C/004702/R/0025 Chiesi Farmaceutici S.p.A., Informed Consent of Trimbow, Rapporteur: Janet Koenig, Co-Rapporteur: Finbarr Leacy, PRAC Rapporteur: Jan Neuhauser

B.2.3. Renewals of Conditional Marketing Authorisations

CRYSVITA - burosumab - EMEA/H/C/004275/R/0031, Orphan Kyowa Kirin Holdings B.V., Rapporteur: Kristina Dunder, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Brigitte Keller-Stanislawski	
Paxlovid - (1r,2s,5s)-n-((1s)-1-cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/R/0023 Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Martin Huber	
Retsevmo - selpercatinib - EMEA/H/C/005375/R/0018 Eli Lilly Nederland B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst	
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/R/0079 AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné	See 9.1

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its October 2022 meeting:
EMEA/H/C/PSUSA/00000403/202202 (bevacizumab) CAPS: **Abevmy** (EMEA/H/C/005327) (bevacizumab), Mylan IRE Healthcare Limited, Rapporteur: Jan Mueller-Berghaus **Alymsys** (EMEA/H/C/005286) (bevacizumab), Mabxience Research SL, Rapporteur: Christian

Gartner
Avastin (EMEA/H/C/000582) (bevacizumab), Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia
Aybintio (EMEA/H/C/005106) (bevacizumab), Samsung Bioepis NL B.V., Rapporteur: Andrea Laslop
MVASI (EMEA/H/C/004728) (bevacizumab), Amgen Technology (Ireland) Unlimited Company, Rapporteur: Eva Skovlund
Onbevzi (EMEA/H/C/005640) (bevacizumab), Samsung Bioepis NL B.V., Rapporteur: Andrea Laslop
Oyavas (EMEA/H/C/005556) (bevacizumab), STADA Arzneimittel AG, Rapporteur: Christian Gartner
Zirabev (EMEA/H/C/004697) (bevacizumab), Pfizer Europe MA EEIG, Rapporteur: Eva Skovlund, PRAC Rapporteur: Anette Kirstine Stark, "25/02/2021 To: 25/02/2022"

EMEA/H/C/PSUSA/00010633/202203
(ribociclib)
CAPS:
Kisqali (EMEA/H/C/004213) (ribociclib), Novartis Europharm Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "13/03/2021 To: 12/03/2022"

EMEA/H/C/PSUSA/00010745/202202
(apalutamide)
CAPS:
Erleada (EMEA/H/C/004452) (apalutamide), Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Tiphaine Vaillant, "14/08/2021 To: 13/02/2022"

EMEA/H/C/PSUSA/00010825/202203
(esketamine (for centrally authorised product only))
CAPS:
Spravato (EMEA/H/C/004535) (esketamine), Janssen-Cilag International N.V., Rapporteur: Martina Weise, PRAC Rapporteur: Kirsti Villikka, "05/09/2021 To: 04/03/2022"

EMEA/H/C/PSUSA/00010851/202203
(isatuximab)
CAPS:
SARCLISA (EMEA/H/C/004977) (isatuximab), sanofi-aventis groupe, Rapporteur: Paula

Boudewina van Hennik, PRAC Rapporteur: Maria del Pilar Rayon, "01/03/2021 To: 01/03/2022"	
EMEA/H/C/PSUSA/00010916/202202 (COVID-19 vaccine (Ad26.COV2-S [recombinant]) (COVID-19 Vaccine Janssen)) CAPS: **JCOVDEN** (EMEA/H/C/005737) (adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein), Janssen-Cilag International N.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Ulla Wändel Liminga, "24/08/2021 To: 24/02/2022"	
EMEA/H/C/PSUSA/00010969/202202 (lonapegsomatropin) CAPS: **Skytrofa** (EMEA/H/C/005367) (lonapegsomatropin), Ascendis Pharma Endocrinology Division A/S, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, "25/08/2021 To: 25/02/2022"	

B.4. EPARs / WPARs

Beyfortus - nirsevimab - EMEA/H/C/005304 AstraZeneca AB, Prevention of RSV lower respiratory tract infection. Immunise infants from birth entering their first Respiratory Syncytial Virus (RSV) season for the prevention of RSV lower respiratory tract disease, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Enjaymo - sutimlimab - EMEA/H/C/005776, Orphan Genzyme Europe BV, treatment of haemolysis in adult patients with cold agglutinin disease (CAD), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
LIVTENCITY - maribavir - EMEA/H/C/005787, Orphan Takeda Pharmaceuticals International AG Ireland Branch, treatment of cytomegalovirus (CMV) infection, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Melatonin Neurim - melatonin - EMEA/H/C/005603 RAD Neurim Pharmaceuticals EEC SARL, treatment of primary insomnia, Informed	For information only. Comments can be sent to the PL in case necessary.

Consent of Circadin, Informed consent application (Article 10c of Directive No 2001/83/EC)	
Mycapssa - octreotide - EMEA/H/C/005826, Orphan Amryt Pharmaceuticals DAC, treatment of acromegaly, Hybrid application (Article 10(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Pyrukynd - mitapivat - EMEA/H/C/005540, Orphan Agios Netherlands B.V., treatment of pyruvate kinase deficiency, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Sorafenib Accord - sorafenib - EMEA/H/C/005921 Accord Healthcare S.L.U., treatment of hepatocellular carcinoma and renal cell carcinoma, Generic, Generic of Nexavar, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Teriflunomide Accord - teriflunomide - EMEA/H/C/005960 Accord Healthcare S.L.U., treatment of multiple sclerosis (MS), Generic, Generic of AUBAGIO, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Teriflunomide Mylan - teriflunomide - EMEA/H/C/005962 Mylan Pharmaceuticals Limited, treatment of multiple sclerosis (MS), Generic, Generic of AUBAGIO, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Teriparatide SUN - teriparatide - EMEA/H/C/005793 Sun Pharmaceutical Industries Europe B.V., treatment of osteoporosis, Hybrid application (Article 10(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Ximluci - ranibizumab - EMEA/H/C/005617 STADA Arzneimittel AG, treatment of neovascular age-related macular degeneration (AMD), Similar biological application (Article 10(4) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Zynlonta - loncastuximab tesirine - EMEA/H/C/005685, Orphan ADC Therapeutics (NL) B.V., treatment of adult patients with relapsed or refractory large B-cell	For information only. Comments can be sent to the PL in case necessary.

lymphoma, New active substance (Article 8(3) of Directive No 2001/83/EC)	
Vabysmo - faricimab - EMEA/H/C/005642 Roche Registration GmbH, treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DME), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

Alecensa - alectinib - EMEA/H/C/004164/II/0041 Roche Registration GmbH, Rapporteur: Filip Josephson Request for Supplementary Information adopted on 01.09.2022.	
Ameluz - 5-aminolevulinic acid - EMEA/H/C/002204/II/0049/G Biofrontera Bioscience GmbH, Rapporteur: Janet Koenig Request for Supplementary Information adopted on 10.06.2022, 14.10.2021.	
Armisarte - pemetrexed - EMEA/H/C/004109/II/0030/G Actavis Group PTC ehf, Rapporteur: Alar Irs Request for Supplementary Information adopted on 22.09.2022.	Request for supplementary information adopted with a specific timetable.
Bavencio - avelumab - EMEA/H/C/004338/II/0037/G Merck Europe B.V., Rapporteur: Filip Josephson	
Benepali - etanercept - EMEA/H/C/004007/II/0065/G Samsung Bioepis NL B.V., Rapporteur: Andrea Laslop Opinion adopted on 06.10.2022. Request for Supplementary Information adopted on 14.07.2022.	Positive Opinion adopted by consensus on 06.10.2022.
Caelyx pegylated liposomal - doxorubicin - EMEA/H/C/000089/II/0103	

Baxter Holding B.V., Rapporteur: Ondřej Slanař	
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0146/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 29.09.2022.	Positive Opinion adopted by consensus on 29.09.2022.
Elaprase - idursulfase - EMEA/H/C/000700/II/0095 Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 22.09.2022. Request for Supplementary Information adopted on 07.07.2022, 24.03.2022.	Positive Opinion adopted by consensus on 22.09.2022.
Entyvio - vedolizumab - EMEA/H/C/002782/II/0070/G Takeda Pharma A/S, Rapporteur: Armando Genazzani Opinion adopted on 29.09.2022. Request for Supplementary Information adopted on 21.07.2022.	Positive Opinion adopted by consensus on 29.09.2022.
Firazyr - icatibant - EMEA/H/C/000899/II/0054/G, Orphan Takeda Pharmaceuticals International AG, Rapporteur: Kristina Dunder Opinion adopted on 22.09.2022. Request for Supplementary Information adopted on 21.07.2022.	Positive Opinion adopted by consensus on 22.09.2022.
Insulin aspart Sanofi - insulin aspart - EMEA/H/C/005033/II/0010/G sanofi-aventis groupe, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 06.10.2022.	Request for supplementary information adopted with a specific timetable.
Lyumjev - insulin lispro - EMEA/H/C/005037/II/0016 Eli Lilly Nederland B.V., Rapporteur: Outi Mäki-Ikola Request for Supplementary Information adopted on 08.09.2022.	
Nexviadyme - avalglucosidase alfa - EMEA/H/C/005501/II/0001, Orphan Genzyme Europe BV, Rapporteur: Andrea Laslop Opinion adopted on 22.09.2022.	Positive Opinion adopted by consensus on 22.09.2022.
Nexviadyme - avalglucosidase alfa - EMEA/H/C/005501/II/0002, Orphan	Positive Opinion adopted by consensus on 22.09.2022.

Genzyme Europe BV, Rapporteur: Andrea Laslop Opinion adopted on 22.09.2022.	
Nexviadyme - avalglucosidase alfa - EMEA/H/C/005501/II/0003/G, Orphan Genzyme Europe BV, Rapporteur: Andrea Laslop Opinion adopted on 06.10.2022.	Positive Opinion adopted by consensus on 06.10.2022.
OPDIVO - nivolumab - EMEA/H/C/003985/II/0124/G Bristol-Myers Squibb Pharma EEIG, Rapporteur: Blanca Garcia-Ochoa Opinion adopted on 06.10.2022.	Positive Opinion adopted by consensus on 06.10.2022.
Paxlovid - (1r,2s,5s)-n-((1s)-1-cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0019/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race	
Pemetrexed Accord - pemetrexed - EMEA/H/C/004072/II/0020 Accord Healthcare S.L.U., Generic, Generic of Alimta, Rapporteur: John Joseph Borg Request for Supplementary Information adopted on 07.07.2022.	
Phesgo - pertuzumab / trastuzumab - EMEA/H/C/005386/II/0012/G Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia Opinion adopted on 06.10.2022. Request for Supplementary Information adopted on 01.09.2022.	Positive Opinion adopted by consensus on 06.10.2022.
Qarziba - dinutuximab beta - EMEA/H/C/003918/II/0047, Orphan EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik Opinion adopted on 06.10.2022.	Positive Opinion adopted by consensus on 06.10.2022.
Remsima - infliximab - EMEA/H/C/002576/II/0117/G Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola Request for Supplementary Information adopted on 29.09.2022.	Request for supplementary information adopted with a specific timetable.
SARCLISA - isatuximab - EMEA/H/C/004977/II/0017/G sanofi-aventis groupe, Rapporteur: Paula	

Boudewina van Hennik	
Spikevax - elasomeran - EMEA/H/C/005791/II/0076/G Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus	
Spikevax - elasomeran - EMEA/H/C/005791/II/0078/G Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus Opinion adopted on 06.10.2022.	Positive Opinion adopted by consensus on 06.10.2022.
Spikevax - elasomeran - EMEA/H/C/005791/II/0079/G Moderna Biotech Spain, S.L., Co-Rapporteur: Andrea Laslop Opinion adopted on 06.10.2022.	Positive Opinion adopted by consensus on 06.10.2022.
Terrosa - teriparatide - EMEA/H/C/003916/II/0026/G Gedeon Richter Plc., Rapporteur: Daniela Philadelphy Request for Supplementary Information adopted on 29.09.2022.	Request for supplementary information adopted with a specific timetable.
Tremfya - guselkumab - EMEA/H/C/004271/II/0034/G Janssen-Cilag International N.V., Rapporteur: Agnes Gyurasics	
Ultomiris - ravulizumab - EMEA/H/C/004954/II/0030 Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa	
Vaniqa - eflornithine - EMEA/H/C/000325/II/0056 Almirall S.A, Rapporteur: Jayne Crowe Opinion adopted on 22.09.2022. Request for Supplementary Information adopted on 10.06.2022.	Positive Opinion adopted by consensus on 22.09.2022.
Voraxaze - glucarpidase - EMEA/H/C/005467/II/0004, Orphan SERB S.A.S., Rapporteur: Ondřej Slanař Opinion adopted on 22.09.2022.	Positive Opinion adopted by consensus on 22.09.2022.
ZYNRELEF - bupivacaine / meloxicam - EMEA/H/C/005205/II/0009/G Heron Therapeutics, B.V., Rapporteur: Alexandre Moreau Request for Supplementary Information adopted on 22.09.2022.	Request for supplementary information adopted with a specific timetable.

WS2283/G **Eucreas-** **EMEA/H/C/000807/WS2283/0098/G** **Galvus-** **EMEA/H/C/000771/WS2283/0077/G** **Icandra-** **EMEA/H/C/001050/WS2283/0103/G** **Jalra-** **EMEA/H/C/001048/WS2283/0080/G** **Xiliarx-** **EMEA/H/C/001051/WS2283/0078/G** **Zomarist-** **EMEA/H/C/001049/WS2283/0100/G** Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder Opinion adopted on 06.10.2022. Request for Supplementary Information adopted on 01.09.2022.	Positive Opinion adopted by consensus on 06.10.2022.
WS2288 **Humalog-** **EMEA/H/C/000088/WS2288/0196** **Liprolog-** **EMEA/H/C/000393/WS2288/0156** Eli Lilly Nederland B.V., Lead Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 01.09.2022.	
WS2309/G **Hexacima-** **EMEA/H/C/002702/WS2309/0135/G** **Hexyon-** **EMEA/H/C/002796/WS2309/0139/G** Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 22.09.2022.	Positive Opinion adopted by consensus on 22.09.2022.
WS2332/G **Ongentys-** **EMEA/H/C/002790/WS2332/0051/G** **Ontilyv-** **EMEA/H/C/005782/WS2332/0005/G** Bial - Portela & Cª, S.A., Lead Rapporteur: Martina Weise Opinion adopted on 22.09.2022.	Positive Opinion adopted by consensus on 22.09.2022.

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

ADCETRIS - brentuximab vedotin - **EMEA/H/C/002455/II/0103, Orphan** Takeda Pharma A/S, Rapporteur: Paula

Boudewina van Hennik, "Update of sections 4.8 and 5.1 of the SmPC to reflect new safety and efficacy information based on long-term data from the second interim analysis of OS (103 events) from study ECHELON-1, undertaken in previously untreated CD30+ Stage IV HL. In addition, following the completion of all specific obligations and considering the recent switch from a conditional to a full MA (variation II-99), the MAH takes the opportunity to propose the removal of the black triangle (regarding additional monitoring) from the SmPC and the Package Leaflet. Further, minor editorial changes are proposed in the SmPC and Package Leaflet and the contact details of the local representatives are being updated in the Package Leaflet."	
Avonex - interferon beta-1A - EMEA/H/C/000102/II/0193 Biogen Netherlands B.V., Rapporteur: Maria Concepcion Prieto Yerro, "Update of sections 4.2 and 4.4 of the SmPC in order to update safety information for the paediatric population based on the final results of the Tecfidera Paediatric study (109MS306) (CONNECT - part 1), submitted as part of the PAM procedure P46/089, availability of data from published literature and post-marketing data from Biogen global safety database; the Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 16.06.2022.	
Benlysta - belimumab - EMEA/H/C/002015/II/0107 GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder, "Update of section 4.4 of the SmPC based on final results from study 205646; this is an interventional Phase III Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination with Rituximab to Adult Subjects with Systemic Lupus Erythematosus (SLE). In addition, the MAH took the opportunity to implement editorial changes." Request for Supplementary Information adopted on 29.09.2022.	Request for supplementary information adopted with a specific timetable.
Betaferon - interferon beta-1b - EMEA/H/C/000081/II/0143/G Bayer AG, Rapporteur: Martina Weise, "Update of sections 4.4 and 4.8 of the SmPC based on	Request for supplementary information adopted with a specific timetable.

pooled clinical trial data from six phase II-IV studies: NASPMS (Study No. 3112), Pivotal RRMS (Study No. 13103), EUSPMS (Study No.93079), BENEFIT (Study No. 304747), BEYOND (Study No. 306440) and BEYOND pilot (Study No. 307000), post-marketing experience, scientific literature and FAERS database; the Package Leaflet is updated accordingly. Update of section 4.8 of the SmPC in order to merge the existing two tables for ADRs, requested by the PRAC following the assessment of PSUSA procedure EMEA/H/C/PSUSA/00001759/202107), based on pooled data from four placebo controlled trials: NASPMS (Study No. 3112), Pivotal RRMS (Study No. 13103), EUSPMS (Study No. 93079), and BENEFIT (Study No. 304747); the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes and to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 06.10.2022.	
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0139 BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "Update of sections 4.8 and 5.1 of the SmPC of COMIRNATY 30 µg concentrate for dispersion for injection and COMIRNATY 30 µg dispersion for injection as well as section 4.8 of the SmPC of COMIRNATY 10 µg concentrate for dispersion for injection in order to update information based on six month post (booster) dose three interim report data in patients aged 16 years of age and above from studies C4591001 and C4591031. Study C4591001 is a phase 1/2/3, placebo-controlled, randomized, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy individuals, while study C4591031 is a phase 3 master protocol to evaluate additional dose(s) of BNT162b2 in healthy individuals previously vaccinated with BNT162b2."	See 9.1
Esperoct - turoctocog alfa pegol - EMEA/H/C/004883/II/0013	

Novo Nordisk A/S, Rapporteur: Andrea Laslop, "Update of section 4.2 of the SmPC in order to delete the statement in reference to previously untreated patients (PUPs) and section 5.1 of the SmPC in order to update information based on final results from study NN7088-3908; this is an open-label single-arm multicentre non-controlled phase 3a trial investigating safety and efficacy of turoctocog alfa pegol (N8-GP) in prophylaxis and treatment of bleeding episodes in previously untreated paediatric patients with severe haemophilia A. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."
Request for Supplementary Information adopted on 21.07.2022.

Extavia - interferon beta-1b - EMEA/H/C/000933/II/0116/G

Novartis Europharm Limited, Informed Consent of Betaferon, Rapporteur: Martina Weise, "Update of sections 4.4 and 4.8 of the SmPC in order to expand the language regarding the risk of injection site infection; the Package Leaflet is updated accordingly.
Update of section 4.8 of the SmPC to merge the existing two tables for ADRs that occurred during clinical trials and those reported post-marketing, requested by PRAC following the assessment of PSUSA procedure (PSUSA/00001759/202107); the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Eylea - aflibercept - EMEA/H/C/002392/II/0080

Bayer AG, Rapporteur: Alexandre Moreau, "Update of sections 4.2 and 5.1 of the SmPC in order to allow the individualisation of the treatment posology for intravitreal aflibercept in diabetic macular edema (DME) indication based on a propensity-score-matching (PSM) analyses on patient-level-data comparison of the two pivotal studies in DME (VIVID & VISTA) versus the independently conducted Protocol T study as well as supporting data from a systematic literature review and confirmatory data from the recently completed VIOLET Phase 3b study. The Package Leaflet is updated accordingly."
Request for Supplementary Information adopted

on 23.06.2022.	
Imbruvica - ibrutinib - EMEA/H/C/003791/II/0075 Janssen-Cilag International N.V., Rapporteur: Filip Josephson, "Update of section 4.2 of the SmPC to incorporate information specific for dose modifications for non-cardiac events and events of cardiac failure or cardiac arrhythmias events based on data pool from clinical studies which included 4 Phase II (PCYC-1102-CA, PCYC-1104-CA, PCYC-1118E, PCYC-1142-CA) and 8 Phase III studies (PCYC-1112-CA, PCYC-1115-CA, CLL3001, PCYC-1130-CA, MCL3001, PCYC-1127-CA, CLL3011, and MCL3002)." Request for Supplementary Information adopted on 21.07.2022.	See 9.1
Imfinzi - durvalumab - EMEA/H/C/004771/II/0050 AstraZeneca AB, Rapporteur: Aaron Sosa Mejia, "Update of section 5.1 of the SmPC in order to include the most recent overall survival (OS) data based on final results from the CASPIAN study (D419QC00001). This is a phase III, randomized, multicenter, open-label, comparative study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for the first-line treatment in patients with extensive disease small-cell lung cancer (SCLC)." Opinion adopted on 29.09.2022.	Positive Opinion adopted by consensus on 29.09.2022.
Jardiance - empagliflozin - EMEA/H/C/002677/II/0071 Boehringer Ingelheim International GmbH, Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC based on a meta-analysis report for the non-interventional study EMPRISE–Europe and Asia (1245.195), undertaken to assess the effectiveness and safety of empagliflozin compared with DPP-4 inhibitors in adult patients with type 2 diabetes. The MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet and to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 22.09.2022.	Request for supplementary information adopted with a specific timetable.
JCOVDEN - adenovirus type 26 encoding	

the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0047/G

Janssen-Cilag International N.V., Rapporteur: Christophe Focke, "Submission of the final reports from the non-clinical studies TV-TEC-207316, TV-TEC-207437, TOX15155, TV-TEC-215524 and TOX15252, listed as category 3 in the RMP. These are non-clinical studies conducted to further characterise the potential mechanisms underlying the important identified risks of thrombosis with thrombocytopenia syndrome (TTS) and thrombocytopenia, including immune thrombocytopenia (ITP)." Request for Supplementary Information adopted on 23.06.2022.

Koselugo - selumetinib - EMEA/H/C/005244/II/0006/G, Orphan

AstraZeneca AB, Rapporteur: Alexandre Moreau, "Submission of the reports for the long-term efficacy and safety updates from study D1532C00057: SPRINT Phase I and SPRINT Phase II Stratum 1 to fulfil the Specific Obligations SOB/003 and SOB/002, respectively, listed in the Annex II of the Product Information. This is a phase I/II study of the mitogen activated protein kinase (MEK) 1 inhibitor selumetinib (AZD6244; HYD-Sulfate) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)." Request for Supplementary Information adopted on 21.07.2022.

LIBTAYO - cemiplimab - EMEA/H/C/004844/II/0031

Regeneron Ireland Designated Activity Company (DAC), Rapporteur: Aaron Sosa Mejia, "Update of sections 4.8 and 5.1 of the SmPC in order to update the list of adverse drug reactions (ADRs) and efficacy information based on final results from study R2810-ONC-1540 in order to fulfil REC/005; this is a nonrandomized, multicenter, phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

LIBTAYO - cemiplimab - EMEA/H/C/004844/II/0032

Regeneron Ireland Designated Activity Company (DAC), Rapporteur: Aaron Sosa Mejia, "Update

of sections 4.8 and 5.1 of the SmPC in order to update the list of adverse drug reactions (ADRs) and efficacy results for the BCC indication based on the primary analysis data from study R2810-ONC-1620 listed in the Annex II; this is a phase 2 study of cemiplimab in patients with advanced basal cell carcinoma who experienced progression of disease on hedgehog pathway inhibitor therapy or were intolerant of prior hedgehog pathway inhibitor therapy. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."	
Methylthioninium chloride Proveblue - methylthioninium chloride - EMEA/H/C/002108/II/0052/G Provepharm SAS, Rapporteur: Kristina Dunder, "Update of sections 4.2 and 5.2 of the SmPC in order to change the posology recommendations in patients with renal and hepatic impairment and update the pharmacokinetic information respectively, based on results from: an open-label, parallel group, population-matched, single-dose study to investigate the influence of renal impairment on the pharmacokinetics of ProvayBlue (Study Report PVP-2016006). The package leaflet and labelling are updated accordingly. The applicant takes this opportunity to update the Product Information according to the QRD template v10.1 and v10.2. Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with other medicinal products and update the pharmacokinetic information respectively, based on results from: an open-label, randomized, two-period, crossover study to assess the effect of a single dose of methylene blue 5 mg/ml on the pharmacokinetics of the probe drugs midazolam, caffeine, warfarin, omeprazole and dextromethorphan in healthy subjects (Study Report PVP-2016004). The package leaflet and labelling are updated accordingly." Request for Supplementary Information adopted on 21.07.2022, 22.04.2022, 16.12.2021.	
Myozyme - alglucosidase alfa - EMEA/H/C/000636/II/0087 Genzyme Europe BV, Rapporteur: Alexandre Moreau, "Update of section 4.8 of the SmPC in order to add palpitations, asthenia, malaise,	Positive Opinion adopted by consensus on 06.10.2022.

feeling cold and blood pressure decreased to the list of adverse drug reactions (ADRs) with frequency "not-known" following the Final Assessment Report for the Post-Authorisation Measure MEAs 024.13 and 0.25.13 (the 2019 Pompe Disease Registry Annual Report) dated 15 October 2020; the Package Leaflet is updated accordingly. In addition, section 4.9 of the SmPC was updated to include further guidance with regards to overdose and the MAH also took the opportunity to update section 5.1 of the SmPC to update the internet website address of the Pompe Registry." Opinion adopted on 06.10.2022. Request for Supplementary Information adopted on 10.06.2022, 07.04.2022, 20.01.2022.	
Norvir - ritonavir - EMEA/H/C/000127/II/0163 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Johann Lodewijk Hillege, "Update of section 4.2 of the SmPC in order to modify administration based on final results from three bioavailability and bioequivalence studies: M11-472, M12-279, and M11-475; the Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."	
NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0011/G Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, "Grouped variation: - C.I.4 (Type II): Update of section 5.1 of the SmPC in order to introduce data on clinical efficacy against the Omicron variant of concern, based on data from study 2019nCoV-101 (Parts 1 and 2), a Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With or Without Matrix-M Adjuvant in Healthy Subjects (NCT04368988), study 2019nCoV-501, a Phase 2a/b, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS)	

With Matrix-M Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV (NCT04533399) and published literature. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to make minor editorial corrections throughout the product information. - C.I.13 (Type II): Submission of the final clinical report from study 2019nCoV-101 (Part 1), a Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With or Without Matrix-M Adjuvant in Healthy Subjects (NCT04368988). This submission addresses the post-authorisation measures MEA 009, REC 041 and REC 042." Request for Supplementary Information adopted on 21.07.2022.	
Onpattro - patisiran - EMEA/H/C/004699/II/0025, Orphan Alnylam Netherlands B.V., Rapporteur: Kristina Dunder, "Update of sections 4.2 and 5.1 of the SmPC based on interim results from study ALN-TTR02-006 listed as a category 3 study in the RMP; this is a multicenter, open-label, extension study to evaluate the long-term safety and efficacy of patisiran in patients with familial amyloidotic polyneuropathy who have completed a prior clinical study with patisiran. In addition, the MAH took the opportunity to update section 3 of the SmPC in order to update the pH ." Request for Supplementary Information adopted on 06.10.2022, 23.06.2022.	Request for supplementary information adopted with a specific timetable.
Padcev - enfortumab vedotin - EMEA/H/C/005392/II/0002 Astellas Pharma Europe B.V., Rapporteur: Aaron Sosa Mejia, "Submission of the final report from study "An Open-label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects with Previously Treated Locally Advanced or Metastatic Urothelial Cancer" (EV-301) listed as a category 3 study. EV-301 is a global, open-label, randomized phase 3 study in adult subjects with locally	Positive Opinion adopted by consensus on 22.09.2022.

advanced or metastatic UC who had received a platinum-containing chemotherapy and had experienced disease progression or relapse during or following treatment with PD-1 or PD-L1 inhibitors." Opinion adopted on 22.09.2022.	
Paxlovid - (1r,2s,5s)-n-((1s)-1-cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0010/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of section 4.8 of the SmPC to add hypersensitivity to the list of adverse drug reactions with frequency common, based on a cumulative search of the MAH safety database; the Package Leaflet is updated accordingly. Update of section 4.5 of the SmPC in order to add drug-drug interaction information with dabigatran (P-gp substrate) based on the clinical study results from study C4671012, a pharmacokinetic study to estimate the effect of Paxlovid on the pharmacokinetics of dabigatran; the Package Leaflet is updated accordingly. Update of section 4.5 of the SmPC in order to update the drug-drug interaction information of midazolam based on the clinical study results from study C4671013, a pharmacokinetic study to estimate the effect of Paxlovid on the pharmacokinetics of midazolam. The MAH is taking the opportunity to include editorial updates in sections 4.3 and 6.1 of the SmPC." Request for Supplementary Information adopted on 06.10.2022, 23.06.2022.	Request for supplementary information adopted with a specific timetable.
Paxlovid - (1r,2s,5s)-n-((1s)-1-cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0016/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of section 4.8 SmPC in order to include the adverse reactions nausea, abdominal pain and malaise based on global safety database of the MAH and Literature Review. The Package Leaflet is updated accordingly."	

Request for Supplementary Information adopted on 01.09.2022.	
Pegasys - peginterferon alfa-2A - EMEA/H/C/000395/II/0112 Zr Pharma& GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, "Update of section 4.8 of the SmPC in order to include information on post-treatment recovery in growth based on final results from study YV25718 listed as a category 3 study in the RMP; this is a Phase IIIb parallel group, open label study of pegylated interferon alfa-2a monotherapy (PEG-IFN, RO0258310) compared to untreated control in children with HBeAg-Positive Chronic Hepatitis B in the immune active phase. The RMP version 9.1 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes in the Package Leaflet." Opinion adopted on 29.09.2022. Request for Supplementary Information adopted on 07.07.2022.	Positive Opinion adopted by consensus on 29.09.2022.
Plenadren - hydrocortisone - EMEA/H/C/002185/II/0038 Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Kristina Dunder, "Update of section 4.4 of the SmPC in order to add a warning on pheochromocytoma crisis following a safety signal. The Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to update the list of local representatives in the Package Leaflet and other minor corrections considered as editorial changes."	
Regkirona - regdanvimab - EMEA/H/C/005854/II/0005 Celltrion Healthcare Hungary Kft., Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC in order to update the description of Phase 3 of study CT-P59 3.2 following finalisation of the clinical study report from study CT-P59 3.2 Part 2." Request for Supplementary Information adopted on 21.07.2022.	
Retsevmo - selpercatinib - EMEA/H/C/005375/II/0016 Eli Lilly Nederland B.V., Rapporteur: Alexandre	

Moreau, "Update of section 4.8 of the SmPC in order to add chylothorax and chylous ascites to the list of adverse drug reactions (ADRs) based on a review of adverse events. The Package Leaflet is updated accordingly."	
Retsevmo - selpercatinib - EMEA/H/C/005375/II/0017 Eli Lilly Nederland B.V., Rapporteur: Alexandre Moreau, "Update of section 4.5 of the SmPC in order to update drug-drug interaction information based on the final results from study J2G-MC-JZJV; this is a phase 1, single-center, open-label, drug-drug interaction (DDI) study to investigate the effect of selpercatinib on the pharmacokinetic profiles of dabigatran, a P-glycoprotein (P-gp) substrate, in healthy volunteers. The Package Leaflet is updated accordingly."	
Ronapreve - casirivimab / imdevimab - EMEA/H/C/005814/II/0007 Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.2, 4.4, 5.1 and 5.2 of the SmPC in order to introduce the proposed dose for SARS-CoV-2 Omicron BA.2, BA.2.12.1, BA.4, and BA.5 subvariants along with dose preparation and infusion instructions for treatment of outpatients and post-exposure prophylaxis as well as to update efficacy and pharmacokinetic information based on pharmacokinetic (PK) modelling data from R10933-PK-21187-SR-01V2 and R10933-R10987-4800mgIV-KRM and in vitro viral neutralisation data from the updated virus neutralisation report R10933-PH-20091-SR-01V7 and its addendum; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."	See 9.1
TAGRISSO - osimertinib - EMEA/H/C/004124/II/0047 AstraZeneca AB, Rapporteur: Blanca Garcia-Ochoa, "Update of section 5.2 of the SmPC based on final results from studies ODIN-BM and ODIN-HV; these are two phase I clinical pharmacology studies conducted in EGFRm+ NSCLC patients (ODIN-BM) and healthy volunteers (ODIN-HV) to determine osimertinib blood-brain barrier (BBB) penetration and brain distribution in patients with brain metastases	

and healthy volunteers with an intact BBB, respectively." Request for Supplementary Information adopted on 07.07.2022.	
Taxotere - docetaxel - EMEA/H/C/000073/II/0141 Sanofi Mature IP, Rapporteur: Alexandre Moreau, "Update of sections 4.4, 4.6 and 5.3 of the SmPC to include further information regarding genotoxicity, pregnancy/lactation exposure with associated adverse outcomes and recommendations regarding use of contraception, and update of section 5.2 of the SmPC regarding the pharmacokinetic terminal elimination half-life (t1/2). The Package Leaflet is updated accordingly."	
Toviaz - fesoterodine - EMEA/H/C/000723/II/0063 Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, "C.I.3 Update of sections 4.2, 5.1 and 5.2 of the SmPC with the results from study A0221047, to evaluate the safety and efficacy of fesoterodine in subjects aged 6 to 17 years with neurogenic detrusor overactivity as requested in the outcome of EMEA/H/C/000723/P46/030.1. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.1." Opinion adopted on 06.10.2022. Request for Supplementary Information adopted on 23.06.2022, 03.03.2022, 14.10.2021.	Positive Opinion adopted by consensus on 06.10.2022.
Translarna - ataluren - EMEA/H/C/002720/II/0068, Orphan PTC Therapeutics International Limited, Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC in order to update efficacy information upon the request by the CHMP following the outcome of P46/026 based on final results from study PTC124-GD-045-DMD (study 045); this is an open-label, single-arm, phase 2 study designed to evaluate the ability of ataluren treatment to increase dystrophin protein levels in muscle cells of subjects with nonsense mutation duchenne muscular dystrophy (nmDMD)." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 06.10.2022.	
Trumenba - meningococcal group B vaccine (recombinant, adsorbed) - EMEA/H/C/004051/II/0037 Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.8 and 5.1 of the SmPC in order to include immunopersistence and booster data based on final results from study B1971035 listed as a part of the paediatric investigation plan; this is a phase 2, randomized, controlled, observer-blinded study conducted to describe the immunogenicity, safety, and tolerability of Bivalent rLP2086 when administered to healthy toddlers aged 12 to <18 months or 18 to <24 months, and the safety and immunogenicity of a booster dose of Bivalent rLP2086. In addition, the MAH is also taking this opportunity to introduce editorial changes in the SmPC and to update the list of local representatives in the Package Leaflet." Opinion adopted on 22.09.2022. Request for Supplementary Information adopted on 16.06.2022, 17.02.2022.	Positive Opinion adopted by consensus on 22.09.2022.
Veklury - remdesivir - EMEA/H/C/005622/II/0037/G Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Grouped variations to update sections 4.5, 5.2 and 6.6 of the SmPC to update prescribing information related to interactions with other medicinal products, effect of intrinsic factors and COVID-19 disease on the pharmacokinetics (PK) of Veklury and its metabolites in the adult population. Data from the Phase 1 drug-drug interaction (DDI) study GS US 540 9013, adult COVID-19 participant PK data collected across two Phase 3 studies (GS-US-540-9012 and CO-US-540-5844), and an exposure-safety analysis are included in addition to nonclinical in vitro drug metabolism studies to complete the metabolism profiling. This variation is submitted to cover recommendations 9, 11, 12 and 13 listed at the time of the conditional marketing authorisation (EMEA/H/C/005622/0000) for Veklury. The Package Leaflet is updated accordingly. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce some linguistic amendments."	

Request for Supplementary Information adopted on 23.06.2022.	
Veltassa - patiromer - EMEA/H/C/004180/II/0029 Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Jayne Crowe, "Update of sections 4.2 and 4.5 of the SmPC in order to introduce new drug-drug interaction information based on results from four in vitro studies: RLY-TR-0174, titled "In Vitro Evaluation of Potential RLY5016S and Immunosuppressant Drug-Drug Interactions"; RLY-TR-018, titled "In Vitro Evaluation of Potential Drug-Drug Interactions Between Patiromer and Sevelamer Hydrochloride"; "In Vitro Evaluation of Drug-Drug Interactions of commonly prescribed renal and cardiovascular Drugs with Patiromer DS" and "Drug-drug interactions of commonly prescribed renal and cardiovascular Drugs with Patiromer DS in a simulated GI tract passage study". The Package Leaflet is updated accordingly." Opinion adopted on 06.10.2022. Request for Supplementary Information adopted on 01.09.2022, 19.05.2022.	Positive Opinion adopted by consensus on 06.10.2022.
Xarelto - rivaroxaban - EMEA/H/C/000944/II/0096 Bayer AG, Rapporteur: Kristina Dunder, "Submission of the final report from study 15786 (COMPASS LTOLE). This is a phase 3, multicenter, randomized, double-blind, double-dummy, active comparator, event-driven study, in which subjects were randomized 1:1:1 to rivaroxaban 2.5 mg bid/ASA 100 mg od, or rivaroxaban 5 mg bid, or ASA 100 mg od."	
WS2241/G **Advagraf- EMEA/H/C/000712/WS2241/0065/G** **Modigraf- EMEA/H/C/000954/WS2241/0039/G** Astellas Pharma Europe B.V., Lead Rapporteur: Jayne Crowe, "Update of sections 4.4, 4.5 and 4.8 of the SmPC in order to add a warning on the adverse reaction Thrombotic microangiopathy (TMA) based on a cumulative review of fatal cases of TMA during treatment with tacrolimus, requested by the PRAC following the assessment of the PSUR (EMEA/H/C/00002839/202103).	

Update of section 4.5 of the SmPC in order to add the drug-drug interaction between tacrolimus and caspofungin based on post-marketing safety report and literature. Update of section 5.2 of the SmPC in order to add that tacrolimus is metabolised by the cytochrome P450-3A5 (CYP3A5) based on post-marketing safety report and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement some editorial changes." Request for Supplementary Information adopted on 10.06.2022.	
WS2244 **Nuwiq-EMEA/H/C/002813/WS2244/0048** **Vihuma-EMEA/H/C/004459/WS2244/0030** Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.8 and 5.1 of the SmPC in order to add safety and efficacy data based on the final CSR from the category 3 study GENA-21b; a prospective, open-label, multicentre phase 3b study to assess the efficacy and safety of personalised prophylaxis with Human-cl rhFVIII in previously treated adult patients with severe haemophilia A. Further, upon request by the CHMP following the assessment of study GENA-05 (P46 013 and P46 014), the MAH is updating the numbers of evaluated subjects in SmPC section 4.8 and is removing of the sentence "A prospective open-label clinical study in PUPs with severe haemophilia A (<1% FVIII:C) is ongoing" in section 5.1 of the SmPC. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 01.09.2022, 16.06.2022, 05.05.2022.	See 9.1
WS2321 **CONTROLOC Control-EMEA/H/C/001097/WS2321/0040** **PANTOZOL Control-EMEA/H/C/001013/WS2321/0042** **SOMAC Control-EMEA/H/C/001098/WS2321/0041** Takeda GmbH, Lead Rapporteur: Silvijus Abramavicius, "Update of sections 4.4 and 4.8 of the SmPC in order to add "Severe Cutaneous Adverse Reactions (SCARs)" information and to add "Acute Generalized Exanthematous	

Pustulosis (AGEP)" to the list of adverse drug reactions (ADRs) with frequency "not know" based on post-marketing experience, adverse reaction databases and literature; the Package Leaflet is updated accordingly. In addition, the MAH proposes to update section 4.5 of the SmPC to introduce information regarding Drug-Laboratory Interactions. Furthermore, the MAH took the opportunity to implement editorial changes and to update the list of local representatives in the Package Leaflet."	
WS2334 **Dovato-EMEA/H/C/004909/WS2334/0034** **Juluca-EMEA/H/C/004427/WS2334/0046** **Tivicay-EMEA/H/C/002753/WS2334/0082** **Triumeq-EMEA/H/C/002754/WS2334/0108** ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson, "Update of section 4.6 of the SmPC in order to update information on pregnancy and breast-feeding based on supporting published medical literature data on DolPHIN-1 (Dolutegravir in pregnant HIV mothers and their neonates, NCT02245022). In addition, administrative changes were included in section 5.3 of the SmPC of Tivicay and Juluca." Opinion adopted on 22.09.2022.	Positive Opinion adopted by consensus on 22.09.2022.
WS2336 **Gardasil-EMEA/H/C/000703/WS2336/0100** **Gardasil 9-EMEA/H/C/003852/WS2336/0058** Merck Sharp & Dohme B.V., Lead Rapporteur: Kristina Dunder, "To update section 5.1 of the SmPC to add the effect of vaccination campaigns on the reduction in the incidence of Juvenile-onset Recurrent Respiratory Papillomatosis (JoRRP) based upon published observational studies."	
WS2342/G **Prezista-EMEA/H/C/000707/WS2342/0119/G** **Rezolsta-EMEA/H/C/002819/WS2342/0049/G** **Symtuza-EMEA/H/C/004391/WS2342/0046/G** Janssen-Cilag International N.V., Lead	Request for supplementary information adopted with a specific timetable.

Rapporteur: Johann Lodewijk Hillege, "Update of section 4.8 of the SmPC in order to add 'crystal nephropathy' to the list of adverse drug reactions (ADRs) with frequency rare based on recent post-marketing data; the Package Leaflets are updated accordingly. In addition, the MAH proposes to update sections 4.4 and 4.6 of the SmPC in order to implement the recommendation of the CHMP to remove the disease information relating to sexual transmission of HIV and to amend the sections related to breast-feeding; the Package Leaflets are updated accordingly." Request for Supplementary Information adopted on 29.09.2022.	

B.5.3. CHMP-PRAC assessed procedures

Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0002 Pfizer Europe MA EEIG, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Jean-Michel Dogné, "Update of sections 4.5, 4.8 and 5.1 of the SmPC to add information regarding the co-administration of Apexxnar with seasonal quadrivalent influenza vaccine (QIV) based on final study results from study B7471004, "A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20 valent Pneumococcal Conjugate Vaccine (20vPnC) When Coadministered with Seasonal Inactivated Influenza Vaccine (SIIV) in Adults ≥65 Years of Age." listed as a category 3 study in the RMP. The Package Leaflet is updated accordingly. The updated RMP version 1.1 has also been submitted." Request for Supplementary Information adopted on 21.07.2022, 19.05.2022.	
EVUSHELD - tixagevimab / cilgavimab - EMEA/H/C/005788/II/0003 AstraZeneca AB, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kimmo Jaakkola, "Update of sections 4.2, 4.8, 4.9, 5.1 and 5.2 of the SmPC in order to change the posology recommendations in the pre-exposure prophylaxis indication based on study TACKLE (D8851C00001). The Package Leaflet is updated accordingly. The	See 9.1

RMP version 2 has also been submitted.”	
Fintepla - fenfluramine - EMEA/H/C/003933/II/0011/G, Orphan Zogenix ROI Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, “Update of sections 4.2 and 5.2 of the SmPC to include the relevant information regarding patients with renal impairment following the study 1902 (Pharmacokinetic study of fenfluramine hydrochloride in subjects with varying degrees of impaired and normal renal function). Update of sections 4.4 and 4.5 of the SmPC in order to reflect the relevant information on CYP1A2 or CYP2B6 or CYP2D6 inducers following the study 1904 (Pharmacokinetic drug-drug interaction study of fenfluramine hydrochloride with and without fluvoxamine (CYP1A2 inhibitor), paroxetine (CYP2D6 inhibitor) and rifampin (CYP2B6 inducer) in healthy subjects). An RMP version 2.2 has also been submitted.” Request for Supplementary Information adopted on 29.09.2022, 07.07.2022, 10.03.2022.	Request for supplementary information adopted with a specific timetable.
Fintepla - fenfluramine - EMEA/H/C/003933/II/0015, Orphan Zogenix ROI Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, “To update sections 4.2 and 5.2 of the SmPC to update the safety information based on final results from study ZX008-1903 listed as a category 3 study in the RMP; this is a Phase 1, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZX008 (Fenfluramine Hydrochloride) in Subjects with Varying Degrees of Hepatic Impairment. The primary objective of this study was to compare the PK of a single dose of ZX008 (fenfluramine HCl) in subjects with varying degrees of hepatic impairment with that of healthy matched control subjects. The updated RMP version 2.7 has also been submitted.” Request for Supplementary Information adopted on 29.09.2022.	Request for supplementary information adopted with a specific timetable.
GIVLAARI - givosiran - EMEA/H/C/004775/II/0011/G, Orphan Alnylam Netherlands B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Martin Huber, “Update of section 5.3 of the	Request for supplementary information adopted with a specific timetable.

SmPC based on final results from study AS1-GLP18-007 listed as a category 3 study in the RMP; This is a 104-week Subcutaneous Injection Carcinogenicity Study in Sprague Dawley Rats. Update of section 5.3 of the SmPC based on final results from study AS1-GLP18-004; This is a 26-week Subcutaneous Injection Carcinogenicity Study in TgRasH2 Mice. The RMP version 2.1 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 29.09.2022.	
GIVLAARI - givosiran - EMEA/H/C/004775/II/0013/G, Orphan Alnylam Netherlands B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Martin Huber, "Submission of the final reports from studies ALN-AS1-003 (study 003) and ALN-AS1-002 (study 002) listed as a category 3 studies in the RMP. Study 003 is a phase 3 randomized, double-blind, placebo-controlled multicenter study with an open-label extension to evaluate the efficacy and safety of givosiran in patients with acute hepatic porphyrias, while study 002 is a multicenter, open-label extension study to evaluate the long-term safety and clinical activity of subcutaneously administered ALN AS1 in patients with acute intermittent porphyria who have completed a previous clinical study with ALN-AS1. The RMP version 2.2 has also been submitted."	
Invokana - canagliflozin - EMEA/H/C/002649/II/0060 Janssen-Cilag International N.V., Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, "Submission of the final report from non-clinical studies 1 and 2, listed as category 3 studies in the RMP, in order to fulfil MEA/007.2. Nonclinical study 1 was designed to evaluate the effects of canagliflozin on ketone clearance and production; nonclinical study 2 objective is to evaluate the effects of canagliflozin on ketone clearance and production during prolonged fast. The RMP version 9.1 has also been submitted." Opinion adopted on 29.09.2022.	Positive Opinion adopted by consensus on 29.09.2022.
Jyseleca - filgotinib -	Positive Opinion adopted by consensus on

EMEA/H/C/005113/II/0018 Galapagos N.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of sections 4.4, 4.6 and 5.1 of the SmPC in order to update information on fertility based on interim results from studies GLPG0634-CL-227 (MANTA Ray) and GS-US-418-4279 (MANTA) listed as a category 3 study in the RMP. The Package Leaflet and Annex II are updated accordingly. The RMP version 4.1 has also been submitted." Opinion adopted on 29.09.2022. Request for Supplementary Information adopted on 01.09.2022.	29.09.2022.
Kaftrio - ivacaftor / tezacaftor / elexacaftor - EMEA/H/C/005269/II/0017/G, Orphan Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, "C.I.4 Update of section 5.3 of the SmPC in order to update the non-clinical information based on final results from a 2-year oral carcinogenicity study in rats (VX-445-TX-015) evaluating the carcinogenic potential of up to 10 mg/kg/day of elexacaftor. An updated RMP (version 6.0) has also been submitted to include the completion of the 2-year carcinogenicity study in rats as well as to update the post-market pregnancy safety information collection form following EMEA/H/C/WS2048. C.I.13 To submit the final report of Tezacaftor Juvenile Toxicity study (VX-661-TX-038)." Opinion adopted on 29.09.2022. Request for Supplementary Information adopted on 07.07.2022, 05.05.2022, 10.02.2022.	Positive Opinion adopted by consensus on 29.09.2022.
Kisplyx - lenvatinib - EMEA/H/C/004224/II/0052 Eisai GmbH, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: David Olsen, "Update of section 4.8 of the SmPC based on pooled safety data including results of study 307, an ongoing, multicenter, randomised, open-label study that is being conducted to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib as first-line (1L) treatment in adults	Request for supplementary information adopted with a specific timetable.

with advanced renal cell carcinoma (RCC). The provision of the CSR addresses the post-authorisation measure MEA/FSR 009.3. The Package Leaflet is updated accordingly. An updated RMP version 15.0 has been submitted." Request for Supplementary Information adopted on 29.09.2022.	
NINLARO - ixazomib - EMEA/H/C/003844/II/0041, Orphan Takeda Pharma A/S, Rapporteur: Armando Genazzani, PRAC Rapporteur: Ulla Wändel Liminga, "Submission of the final report from study NSMM-5001 (INSIGHT) listed as a Specific Obligation in the Annex II of the Product Information. This is a global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients. The Annex II and the RMP (submitted version 9.0) are updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI." Request for Supplementary Information adopted on 29.09.2022.	Request for supplementary information adopted with a specific timetable.
Ondexxya - andexanet alfa - EMEA/H/C/004108/II/0033 AstraZeneca AB, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, "Update of section 5.1 of the SmPC based on interim results from the PK/PD study listed as a specific obligation in the Annex II in order to fulfil SOB 1 and SOB 3; this is a PK and PK/PD Analysis of Intravenously Administered Andexanet after dosing to steady state with a factor Xa inhibitor, rivaroxaban or Apixaban, in healthy subjects and patients who have acute major bleeding. In addition, the MAH took the opportunity to implement editorial changes in Annex II of the SmPC. The RMP version 3.0 has also been submitted."	
Paxlovid - (1r,2s,5s)-n-((1s)-1-cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0007 Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Martin Huber, "Submission of the final report from study	Positive Opinion adopted by consensus on 29.09.2022.

C4671010 listed as a category 3 study in the RMP. This is a phase I, non-randomized, open label study to assess the pharmacokinetics, safety and tolerability of PF-07321332 boosted with ritonavir in adults with moderate hepatic impairment and individuals with normal hepatic function. The RMP version 2.2 has been approved." Opinion adopted on 29.09.2022. Request for Supplementary Information adopted on 01.09.2022, 10.06.2022.	
Polivy - polatuzumab vedotin - EMEA/H/C/004870/II/0018, Orphan Roche Registration GmbH, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ulla Wändel Liminga, "Submission of the final report from study GO29365 listed as a category 3 study in the RMP in order to address MEA/002. This is a phase Ib/II, multicenter, open-label study evaluating the safety, tolerability, and anti-tumour activity of polatuzumab vedotin in combination with rituximab or obinutuzumab plus bendamustine in patients with R/R follicular lymphoma or R/R diffuse large B-cell lymphoma. The RMP version 3.0 has also been submitted." Request for Supplementary Information adopted on 29.09.2022.	Request for supplementary information adopted with a specific timetable.
Scintimun - besilesomab - EMEA/H/C/001045/II/0015 CIS BIO International, PRAC Rapporteur: Maria del Pilar Rayon, "Submission of the final report from the clinical study AG-2012 - Non interventional controlled survey on the impact of Scintimun administered for scintigraphic imaging on diagnostic thinking and management of patient with suspicion of peripheral osteomyelitis, listed as a category 3 study in the RMP - MEA 08.4. An updated RMP version 15 was submitted." Opinion adopted on 29.09.2022. Request for Supplementary Information adopted on 10.06.2022.	Positive Opinion adopted by consensus on 29.09.2022.
Trecondi - treosulfan - EMEA/H/C/004751/II/0013, Orphan medac Gesellschaft fur klinische Spezialpraparate mbH, Rapporteur: Fátima Ventura, PRAC Rapporteur: Julia Pallos, "Update of section 5.3 of the SmPC in order to update the description of non-clinical information	Positive Opinion adopted by consensus on 29.09.2022.

regarding musculoskeletal and connective tissue disorders in form of lympho-histiocytic infiltration in the skeletal muscles and renal and urinary disorders which show up as haematuria. These new determinations are based on results from study LPT 37259. A revised RMP version 1.2 was submitted." Opinion adopted on 29.09.2022. Request for Supplementary Information adopted on 07.07.2022.	
Vokanamet - canagliflozin / metformin - EMEA/H/C/002656/II/0064 Janssen-Cilag International N.V., Rapporteur: Martina Weise, PRAC Rapporteur: Menno van der Elst, "Submission of the final report from non-clinical studies 1 and 2, listed as category 3 studies in the RMP in order to fulfil MEA/006.2. Nonclinical study 1 was designed to evaluate the effects of canagliflozin on ketone clearance and production; nonclinical study 2 objective is to evaluate the effects of canagliflozin on ketone clearance and production during prolonged fast. The RMP version 9.1 has also been submitted." Opinion adopted on 29.09.2022.	Positive Opinion adopted by consensus on 29.09.2022.
WS2318/G **Ebymect-** **EMEA/H/C/004162/WS2318/0058/G** **Edistride-** **EMEA/H/C/004161/WS2318/0056/G** **Forxiga-** **EMEA/H/C/002322/WS2318/0077/G** **Qtern-** **EMEA/H/C/004057/WS2318/0036/G** **Xigduo-** **EMEA/H/C/002672/WS2318/0068/G** AstraZeneca AB, Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Mari Thorn, "C.I.4 Update of section 4.4 of the SmPC in order to remove the potential risk of Lower Limb Amputation (LLA) based on studies D1690C00018, D1690C00019, DECLARE, DAPA-HF, DAPA-CKD, and DELIVER. The Package Leaflet are updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to align it with the latest QRD template. In addition, the MAH took the opportunity to update the list of local representatives in the	Request for supplementary information adopted with a specific timetable.

Qtern Package Leaflet. C.I.11.z Submission of an updated RMP in order to align the EU RMPs for the FDCs Xigduo, Ebymect and Qtern, to recently approved updates to the Forxiga EU RMP. C.I.z Update of section 4.5 of the SmPC to include a further PI harmonisation to address the consideration raised by PRAC and CHMP during the ongoing dapagliflozin procedure PSUSA/00010029/202110. The Forxiga RMP and Edistride RMP version 28 have been submitted. The Qtern RMP version 7 has been submitted. The Xigduo RMP and Ebymect RMP version 13 have been submitted." Request for Supplementary Information adopted on 29.09.2022.	

B.5.4. PRAC assessed procedures

PRAC Led **Cancidas - caspofungin - EMEA/H/C/000379/II/0078** Merck Sharp & Dohme B.V., PRAC Rapporteur: Jo Robays, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of an updated RMP version 4.2 in order to remove safety concerns and align it with the EU GVP Module V (Revision 2)." Opinion adopted on 29.09.2022. Request for Supplementary Information adopted on 01.09.2022.	Positive Opinion adopted by consensus on 29.09.2022.
PRAC Led **Entyvio - vedolizumab - EMEA/H/C/002782/II/0073** Takeda Pharma A/S, PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "Submission of the final report from study MLN0002_401 listed as a category 3 study in the RMP in order to fulfil MEA/001.2; this is an international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn's disease. The RMP version 8.0 has also been submitted." Request for Supplementary Information adopted on 29.09.2022.	Request for supplementary information adopted with a specific timetable.

PRAC Led **HEPLISAV B - hepatitis B surface antigen - EMEA/H/C/005063/II/0015** Dynavax GmbH, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final report from the study HBV-26: Post-Marketing Observational Surveillance Study to Evaluate the Incidence of New-Onset Immune-mediated Diseases, Herpes Zoster, and Anaphylaxis, listed as a category 3 post-authorisation safety study (PASS) in the RMP. This is a post-marketing observational surveillance study comparing the incidence of new-onset immune-mediated diseases, herpes zoster, and anaphylaxis in recipients of HEPLISAV B with recipients of another hepatitis B vaccine. The RMP version 1.3 has also been submitted. The requested variation proposed amendments to the Risk Management Plan (RMP)." Opinion adopted on 29.09.2022. Request for Supplementary Information adopted on 10.06.2022.	Positive Opinion adopted by consensus on 29.09.2022.
PRAC Led **Idacio - adalimumab - EMEA/H/C/004475/II/0017** Fresenius Kabi Deutschland GmbH, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of an updated RMP version 6 in order to propose a continuation of the observational registry (RABBIT) study #1 (Study Identifier: FKS0-000-RAB) and the cancelation of the observational registry (IBD UK) (Study Identifier: FKS0-000-IBD). In addition, the MAH took the opportunity to align the RMP with the current approved RMP of the reference product." Opinion adopted on 29.09.2022.	Positive Opinion adopted by consensus on 29.09.2022.
PRAC Led **Myozyme - alglucosidase alfa - EMEA/H/C/000636/II/0090** Genzyme Europe BV, PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Alexandre Moreau, "Update of SmPC section 4.8 to include the new ADRs "somnolence", "throat irritation" and "infusion site pruritus" with the frequency 'not known', and SmPC section 4.7 to include "somnolence", and "tremor" and "hypotension"	Positive Opinion adopted by consensus on 29.09.2022.

for consistency, based on the final report from non-interventional PASS Pompe Safety Sub-Registry - AGLU06909/LTS13930. This final study report is submitted to address the assessment report conclusion of the Pompe registry report 2020 (MEA024.15 and MEA025.15 Annual Pompe Registry Report 2020). The Package Leaflet is updated accordingly." Opinion adopted on 29.09.2022. Request for Supplementary Information adopted on 05.05.2022.	
PRAC Led **Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/0054** Orexigen Therapeutics Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of the final report from study NB-542 listed as a category 3 PASS in the RMP. This is a cross-sectional survey aimed to evaluate the effectiveness of the Mysimba Physician Prescribing Checklist (PPC) among physicians in the EU. The RMP version 12.6 has also been submitted." Request for Supplementary Information adopted on 29.09.2022, 10.06.2022, 10.02.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0022** Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on pericarditis and myocarditis and to add pericarditis and myocarditis to the list of adverse drug reactions (ADRs) with frequency not known following the outcome of MEA/014.4 based on PRAC assessment on pericarditis and myocarditis. The Package Leaflet is updated accordingly."	
PRAC Led **Obizur - susoctocog alfa - EMEA/H/C/002792/II/0049** Baxalta Innovations GmbH, PRAC Rapporteur:	Request for supplementary information adopted with a specific timetable.

Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final report for study 241501 listed as a category 2 study in the RMP in order to fulfil SOB/001.4. This is a prospective and retrospective, non-interventional post-authorisation safety study (PASS) to evaluate the safety and effectiveness of Obizur in real-life practice. The RMP version 6.0 has also been submitted." Request for Supplementary Information adopted on 29.09.2022.	
PRAC Led **PecFent - fentanyl - EMEA/H/C/001164/II/0054** Kyowa Kirin Holdings B.V., Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of an updated RMP (version 7.1) in line with the outcome of the last PSUR single assessment (PSUSA) procedure (PSUSA 00001369/202004) finalised in January 2021 in order to update the key messages of the educational materials in line with Instanyl (fentanyl). As a result, Annex II-D on 'Conditions or restrictions with regard to the safe and effective use of the medicinal product' is updated accordingly. Finally, the MAH took the opportunity to bring the RMP in line with revision 2 of GVP module V on 'Risk management systems' and the product information in line with the latest quality review of documents (QRD) template (version 10.2). The requested variation proposed amendments to the Annex II and to the Risk Management Plan (RMP)." Opinion adopted on 29.09.2022. Request for Supplementary Information adopted on 07.07.2022, 10.03.2022, 28.10.2021.	Positive Opinion adopted by consensus on 29.09.2022.
PRAC Led **Praluent - alirocumab - EMEA/H/C/003882/II/0072** sanofi-aventis groupe, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final report from study ALIROC07997 listed as a category 3 study in the RMP. This is a post-authorisation safety study (PASS) using healthcare databases to monitor the safety of alirocumab in HIV patients. The RMP version 7.0 has also been submitted."	Positive Opinion adopted by consensus on 29.09.2022.

Opinion adopted on 29.09.2022.	
PRAC Led **Spikevax - elasomeran - EMEA/H/C/005791/II/0077** Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "Update of section 4.8 of the SmPC to include 'Acute and Delayed urticaria' as an adverse reaction, with the frequency 'Rare', as requested by the PRAC in the 13th Safety Summary Report (EMEA/H/C/005791/MEA/011.12). The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 29.09.2022.	Request for supplementary information adopted with a specific timetable.
PRAC Led **WS2212** **Effentora-EMEA/H/C/000833/WS2212/0060** Teva B.V., Lead Rapporteur: Janet Koenig, Lead PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of an updated RMP version 5.1 in order to reformat the RMP according to the revised guidance on GVP Module V (revision 2) and to implement PRAC comments arising from previous assessments as follows: - Revision of the list of safety concerns; - Implementation of key messages in educational materials adopted by PRAC for Instanyl; - Revision of Annex 6 to include verbatim the text adopted by PRAC for Instanyl as presented in Annex 2 of the PRAC PSUSA AR; - Revision of the use of digital access to educational material; - Explanation of the role of the Health Products Regulatory Authority (HPRA)'s CAPA being no longer found to be a trigger of the current RMP update. The 'additional risk minimisation measures' in the Annex II of the product information have been updated accordingly." Opinion adopted on 29.09.2022. Request for Supplementary Information adopted on 07.07.2022, 10.03.2022.	Positive Opinion adopted by consensus on 29.09.2022.
PRAC Led **WS2306**	Request for supplementary information adopted with a specific timetable.

Aripiprazole Mylan Pharma- **EMEA/H/C/003803/WS2306/0020** Mylan Pharmaceuticals Limited, Generic, Generic of Abilify, Lead Rapporteur: Eva Skovlund, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "To align the safety concerns in the RMP with the reference product. In addition, nationally authorised product has been included in the RMP for the company." Request for Supplementary Information adopted on 29.09.2022.	
PRAC Led **WS2320** **Stribild-EMEA/H/C/002574/WS2320/0120** **Truvada-** **EMEA/H/C/000594/WS2320/0177** Gilead Sciences Ireland UC, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "To update Annex II and the RMP for Truvada and Stribild to version 18.1 and 14.1 to remove of the paediatric additional Risk Minimisation Measures (aRMMs) for HIV indication. In addition, the MAH took the opportunity to introduce changes to the PI." Request for Supplementary Information adopted on 29.09.2022.	Request for supplementary information adopted with a specific timetable.

B.5.5. CHMP-CAT assessed procedures

Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - **EMEA/H/C/004731/II/0003, ATMP** Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Armando Genazzani Request for Supplementary Information adopted on 15.07.2022.	
Imlygic - talimogene laherparepvec - **EMEA/H/C/002771/II/0057, ATMP** Amgen Europe B.V., Rapporteur: Maija Tarkkanen, CHMP Coordinator: Johanna Lähteenvuo, "Update to sections 4.4 and 4.8 of the SmPC to revise the safety instructions regarding the risk of disseminated herpetic infection adverse drug reactions following an MAH review of aggregate safety data of herpetic	

and disseminated herpetic infections that were reported in patients who were not immunocompromised and those who were immunocompromised. The Package Leaflet is updated accordingly.”	
Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0053, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang, “Submission of the final report from study CCTL019H2301 (BELINDA) listed as an obligation in the Annex II of the Product Information. This is a randomized open-label parallel-group multicenter Phase III trial to evaluate the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory B-cell aggressive NHL after failure of rituximab and anthracycline containing first-line immune-chemotherapy. The Annex II is updated accordingly.” Request for Supplementary Information adopted on 13.05.2022.	
Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0059, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang, “Update of section 5.1 of the SmPC based on a subgroup analysis from CCTL019B2401 (B2401) disease registry listed as a PAES (ANX006) in the Annex II; this is a non-interventional study to evaluate the efficacy and safety of Kymriah in ALL patients below the age of 3 years. In addition, the MAH took the opportunity to update Annex II.D of the SmPC to reflect the fulfilment of the PAES.” Request for Supplementary Information adopted on 15.07.2022.	

B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2311/G **Advagraf-**	

EMEA/H/C/000712/WS2311/0068/G **Modigraf-** **EMEA/H/C/000954/WS2311/0043/G** Astellas Pharma Europe B.V., Lead Rapporteur: Jayne Crowe	
WS2314 **Aerius-EMEA/H/C/000313/WS2314/0103** **Azomyr-** **EMEA/H/C/000310/WS2314/0107** **Neoclarityn-** **EMEA/H/C/000314/WS2314/0101** Organon N.V., Duplicate, Duplicate of Allex (SRD), Azomyr, Opulis (SRD), Lead Rapporteur: Christophe Focke Opinion adopted on 22.09.2022.	Positive Opinion adopted by consensus on 22.09.2022.
WS2315/G **Biktarvy-** **EMEA/H/C/004449/WS2315/0051/G** **Descovy-** **EMEA/H/C/004094/WS2315/0058/G** **Genvoya-** **EMEA/H/C/004042/WS2315/0084/G** **Odefsey-** **EMEA/H/C/004156/WS2315/0055/G** **Vemlidy-** **EMEA/H/C/004169/WS2315/0041/G** Gilead Sciences Ireland UC, Lead Rapporteur: Bruno Sepodes, Request for Supplementary Information adopted on 06.10.2022.	Request for supplementary information adopted with a specific timetable.
WS2328 **HyQvia-EMEA/H/C/002491/WS2328/0082** **Kiovig-EMEA/H/C/000628/WS2328/0119** Takeda Manufacturing Austria AG, Lead Rapporteur: Jan Mueller-Berghaus	
WS2341 **Aflunov-** **EMEA/H/C/002094/WS2341/0081** **Foclivia-** **EMEA/H/C/001208/WS2341/0078** Seqirus S.r.l, Lead Rapporteur: Armando Genazzani Opinion adopted on 29.09.2022.	Positive Opinion adopted by consensus on 29.09.2022.
WS2350/G **Neupro-** **EMEA/H/C/000626/WS2350/0094/G** UCB Pharma S.A., Lead Rapporteur: Bruno	

Sepodes

WS2352
Mirapexin-
EMEA/H/C/000134/WS2352/0103
Sifrol-EMEA/H/C/000133/WS2352/0094
Boehringer Ingelheim International GmbH, Lead Rapporteur: Thalia Marie Estrup Blicher

WS2354/G
Abseamed-
EMEA/H/C/000727/WS2354/0100/G
Binocrit-
EMEA/H/C/000725/WS2354/0099/G
Epoetin alfa Hexal-
EMEA/H/C/000726/WS2354/0099/G
Sandoz GmbH, Lead Rapporteur: Alexandre Moreau

B.5.9. Information on withdrawn type II variation / WS procedure

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

latanoprost - EMEA/H/C/005933
Reduction of elevated intraocular pressure (IOP)

dabrafenib - EMEA/H/C/005885, Orphan
Novartis Europharm Limited, Treatment of glioma

trametinib - EMEA/H/C/005886, Orphan
Novartis Europharm Limited, Treatment of paediatric patients aged 1 year and older with glioma

tocilizumab - EMEA/H/C/005984
treatment of rheumatoid arthritis, active systemic juvenile idiopathic arthritis (sJIA), juvenile idiopathic polyarthritis (pJIA), chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome (CRS) and COVID-19

fezolinetant - EMEA/H/C/005851
treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause

zilucoplan - EMEA/H/C/005450, Orphan
UCB Pharma S.A., treatment of generalised

myasthenia gravis in adults

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

Esperoct - turoctocog alfa pegol - EMEA/H/C/004883/X/0016

Novo Nordisk A/S, Rapporteur: Andrea Laslop, "Extension application to add two new strengths of 4000 IU and 5000 IU powder and solvent for solution for injection."

Ofev - nintedanib - EMEA/H/C/003821/X/0052/G

Boehringer Ingelheim International GmbH, Rapporteur: Finbarr Leacy, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Nikica Mirošević Skvrce, "Extension application to add a new strength of 25 mg soft capsule grouped with a type II variation C.I.6.a to add a new indication of treatment of fibrosing Interstitial Lung Diseases (ILDs) in children and adolescents from 6 to 17 years of age, based on results from study 1199 0337 (InPedILD); a randomised, placebo-controlled, double-blind, multicentre, multinational, phase III clinical trial undertaken to evaluate dose-exposure and safety of nintedanib on top of standard of care in children and adolescents (6 to 17 years old) with clinically significant fibrosing ILD. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes to the list of local representatives in the Package Leaflet. The updated RMP version 12.0 is also submitted."

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

in vitro diagnostic medical device - EMEA/H/D/006107

In-vitro qualitative immunohistochemical detection of programmed death-ligand 1 (PD-L1)

Request for Supplementary Information adopted on 15.09.2022.

B.6.4. Annual Re-assessments: timetables for adoption

Brineura - cerliponase alfa -
EMEA/H/C/004065/S/0038, Orphan
BioMarin International Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Mari Thorn

Increlex - mecasermin -
EMEA/H/C/000704/S/0078
Ipsen Pharma, Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Kirsti Villikka

Strensiq - asfotase alfa -
EMEA/H/C/003794/S/0059, Orphan
Alexion Europe SAS, Rapporteur: Armando Genazzani, PRAC Rapporteur: Rhea Fitzgerald

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

Aimovig - erenumab -
EMEA/H/C/004447/R/0024
Novartis Europharm Limited, Rapporteur: Kristina Dunder, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Kirsti Villikka

Carmustine Obvius - carmustine -
EMEA/H/C/004326/R/0009
Obvius Investment B.V, Generic, Rapporteur: Elita Poplavska, PRAC Rapporteur: Jan Neuhauser

Hefiya - adalimumab -
EMEA/H/C/004865/R/0038
Sandoz GmbH, Duplicate, Duplicate of Hyrimoz, Rapporteur: Daniela Philadelphy, Co-Rapporteur: Finbarr Leacy, PRAC Rapporteur: Ulla Wändel Liminga

Hyrimoz - adalimumab -
EMEA/H/C/004320/R/0037
Sandoz GmbH, Rapporteur: Daniela Philadelphy, Co-Rapporteur: Finbarr Leacy, PRAC Rapporteur: Ulla Wändel Liminga

Pemetrexed Krka - pemetrexed -
EMEA/H/C/003958/R/0009
KRKA, d.d., Novo mesto, Generic, Generic of Alimta, Rapporteur: Hrefna Gudmundsdottir, PRAC Rapporteur: Tiphaine Vaillant

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

Adempas - riociguat - EMEA/H/C/002737/II/0037 Bayer AG, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Kimmo Jaakkola, "Extension of indication to include treatment of pulmonary arterial hypertension (PAH) in paediatric patients aged 6 to less than 18 years of age with WHO Functional Class (FC) I to III in combination with endothelin receptor antagonists with or without prostanoids for ADEMPAS, based on results from pivotal study PATENT-CHILD (Study 15681); this is a Phase III, Open-label, individual dose titration study to evaluate safety, tolerability and pharmacokinetics of riociguat in children from 6 to less than 18 years of age with PAH; As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.1 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet."	
Bimzelx - bimekizumab - EMEA/H/C/005316/II/0010 UCB Pharma S.A., Rapporteur: Finbarr Leacy, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Liana Gross-Martirosyan, "Extension of indication to include treatment of adults with active axial spondyloarthritis (axSpA), including non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS, radiographic axial spondyloarthritis), based on interim results from two interventional and controlled phase III clinical studies: AS0010 (BE MOBILE 1) and AS0011 (BE MOBILE 2), which provide evidence of the efficacy and safety of bimekizumab in axSpA (nr-axSpA and AS), both compared to placebo treatment. Further supportive data is provided by the results of a phase 2a exploratory study (AS0013), a phase 2b, dose-ranging study (AS0008) and its ongoing follow-on phase 2b open-label extension (OLE) study	

(AS0009). As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.2 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.2 rev.1."

Bimzelx - bimekizumab - EMEA/H/C/005316/II/0011

UCB Pharma S.A., Rapporteur: Finbarr Leacy, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Liana Gross-Martirosyan,

"Extension of indication to include treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to one or more DMARDs for BIMZELX, based on interim results of a Phase III study in biological DMARD naïve study participants (PA0010; BE OPTIMAL) and the final results of the Phase III study in study participants who are inadequate responders (inadequate response or intolerant) to ≤2 prior TNF inhibitors (PA0011; BE COMPLETE). Both Phase III studies are interventional studies aimed to evaluate the efficacy and safety of bimekizumab. For PA0010, the Initial Treatment Period was placebo- and no inferential active reference (adalimumab)-controlled, while PA0011 was placebo-controlled. Further supportive data comprise the results of a Phase 1 study (PA0007), a Phase 2b dose-finding study (PA0008) and a Phase 2 open label extension study (PA0009). A Phase 3 open-label extension study is currently ongoing (PA0012). As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 to the SmPC have been updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.2 rev.1. As part of the application the MAH is requesting a 1-year extension of the market protection."

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

NexoBrid - concentrate of proteolytic enzymes enriched in bromelain - EMEA/H/C/002246/II/0058, Orphan

MediWound Germany GmbH, Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber,

"Extension of current indication for removal of eschar in adults with deep partial- and full-thickness thermal burns to the paediatric population for NexoBrid based on interim results from study MW2012-01-01 (CIDS study), listed as study MW2012-01-01 is a 3-stage, multi-centre, multi-national, randomised, controlled, open label, 2 arm study aiming to demonstrate the superiority of NexoBrid treatment over SOC treatment in paediatric patients (aged 0 to 18 years) with deep partial thickness (DPT) and full thickness (FT) thermal burns of 1% to 30% of total body surface area (TBSA).
As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 9 of the RMP has also been submitted."

OPDIVO - nivolumab - EMEA/H/C/003985/II/0125/G

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Extension of indication to include adolescent patients aged 12 years and older in treatment of advanced (unresectable or metastatic) melanoma (nivolumab monotherapy), treatment of advanced (unresectable or metastatic) melanoma (nivolumab in combination with ipilimumab) and adjuvant treatment of melanoma (nivolumab monotherapy) for Opdivo, based on results from a nonclinical biomarker study (Expression of PD-L1 (CD274), and characterisation of tumour infiltrating immune cells in tumours of paediatric origin), also based on results from a Phase 1/2 clinical study (CA209070, A Phase 1/2 Study of Nivolumab (Ind# 124729) In Children, Adolescents, And Young Adults With Recurrent Or Refractory Solid Tumours As A Single Agent And In Combination With Ipilimumab) and a modelling and simulation study. As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated.
The Package Leaflet is updated in accordance. Version 30.0 of the RMP has also been submitted."

RoActemra - tocilizumab - EMEA/H/C/000955/II/0114

Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte

Keller-Stanislawski, "Extension of indication to include treatment of new indication for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) for RoActemra, based on final results from the pivotal Phase III study WA29767 (focuSSced) entitled, "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis" and the supportive Phase II/III study WA27788 (faSScinate) entitled, "A Phase II/III, Multicenter, Randomized, Double-blind, Placebo-controlled Study To Assess The Efficacy And Safety Of Tocilizumab Versus Placebo In Patients With Systemic Sclerosis". As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 28 of the RMP has also been submitted."	
Rubraca - rucaparib - EMEA/H/C/004272/II/0036 Clovis Oncology Ireland Limited, Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Ulla Wändel Liminga, "Extension of indication to include maintenance treatment of adult patients with advanced (FIGO Stages III and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to first-line platinum-based chemotherapy for RUBRACA, based on interim results from study CO-338-087 (ATHENA); this is a Phase III, randomized, double-blind, dual placebo controlled study of rucaparib as monotherapy and in combination with nivolumab in patients with newly diagnosed EOC, FTC, or PPC who have responded to their first-line treatment (surgery and platinum-based chemotherapy). As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.3 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection."	Request for 1 year of market protection for a new indication (Article 14(11) of Regulation

(EC) 726/2004)

Tenkasi - oritavancin - EMEA/H/C/003785/II/0037

Menarini International Operations Luxembourg S.A., Rapporteur: Janet Koenig, PRAC Rapporteur: Adam Przybylkowski, "Extension of indication to include treatment of paediatric population, aged between 3 months and less than 18 years for Tenkasi (oritavancin) 400 mg based on interim results from study TMC-ORI-11-01; this is a multicenter, open-label, dose-finding study of oritavancin single dose infusion in paediatric subjects less than 18 years of age with suspected or confirmed bacterial infections. The purpose of this Phase 1 study is to evaluate the safety, tolerability and PK of oritavancin in paediatric subjects and determine the optimal dose for a Phase 2 trial in paediatric subjects with ABSSSI. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.0 of the RMP has also been submitted.
In addition, the MAH is also taking this opportunity to update the contact details of the local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.2 rev 1."

Ultomiris - ravulizumab - EMEA/H/C/004954/II/0032

Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Kimmo Jaakkola, "Extension of indication to include the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin 4 (AQP4) antibody-positive, based on interim results from study ALXN1210-NMO-307; this is a phase 3, external placebo-controlled, open-label, multicenter study to evaluate the efficacy and safety of ravulizumab in adult patients with NMOSD. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Wegovy - semaglutide -

EMEA/H/C/005422/II/0009 Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Mari Thorn, "Extension of indication to include treatment of adolescents for weight management for Wegovy based on final results from study NN9536-4451; this trial was conducted to assess the effect and safety of semaglutide in the paediatric population in order to address the unmet need for treatment of adolescents ages 12 to <18 years with obesity. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.2."	
Yervoy - ipilimumab - EMEA/H/C/002213/II/0100 Bristol-Myers Squibb Pharma EEIG, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Menno van der Elst, "Extension of indication to include in combination with nivolumab the treatment of adolescents (12 years of age and older) for advanced (unresectable or metastatic) melanoma, based on the pivotal study CA209070; this is a multicentre, open-label, single arm, phase 1/2 trial of nivolumab +/- ipilimumab in children, adolescents and young adults with recurrent or refractory solid tumours or lymphomas. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 38.0 of the RMP has also been submitted."	

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

CEVENFACTA - eptacog beta (activated) - EMEA/H/C/005655/II/0001 Laboratoire Francais du Fractionnement et des Biotechnologies, Rapporteur: Andrea Laslop	
COMIRNATY - tozinameran - EMEA/H/C/005735/II/0146/G BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson	See B.5.1

Defitelio - defibrotide - EMEA/H/C/002393/II/0059, Orphan
Gentium S.r.l., Rapporteur: Kristina Dunder

Fasturtec - rasburicase - EMEA/H/C/000331/II/0064/G
sanofi-aventis groupe, Rapporteur: Johann Lodewijk Hillege

Flucelvax Tetra - influenza vaccine surface antigen inactivated prepared in cell cultures - EMEA/H/C/004814/II/0029
Seqirus Netherlands B.V., Rapporteur: Sol Ruiz

Gardasil 9 - human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) - EMEA/H/C/003852/II/0060/G
Merck Sharp & Dohme B.V., Rapporteur: Kristina Dunder

JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0064
Janssen-Cilag International N.V., Rapporteur: Christophe Focke

Jivi - damoctocog alfa pegol - EMEA/H/C/004054/II/0025/G
Bayer AG, Rapporteur: Thalia Marie Estrup Blicher

NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0025/G
Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege

NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0027
Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege

Ozurdex - dexamethasone - EMEA/H/C/001140/II/0043/G
AbbVie Deutschland GmbH & Co. KG, Rapporteur: Maria Concepcion Prieto Yerro

Paxlovid - (1r,2s,5s)-n-((1s)-1-cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido) butanoyl)-6,6-dimethyl-3-

azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0028/G
Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race

ReFacto AF - moroctocog alfa - EMEA/H/C/000232/II/0165/G
Pfizer Europe MA EEIG, Rapporteur: Thalia Marie Estrup Blicher

Spikevax - elasomeran - EMEA/H/C/005791/II/0084/G
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, "B.I.a.6.a (Type II): Addition of a new strain (Omicron BA.4-5) resulting in a new Spikevax bivalent Original/Omicron BA.4-5 (50 µg elasomeran/50 µg davesomeran)/mL 0.1 mg/mL dispersion for injection presentation. The Annex A, the SmPC, the Annex II, the labelling and the Package Leaflet are updated accordingly.

Strensiq - asfotase alfa - EMEA/H/C/003794/II/0060/G, Orphan
Alexion Europe SAS, Rapporteur: Armando Genazzani

TRODELVY - sacituzumab govitecan - EMEA/H/C/005182/II/0017
Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus

Trumenba - meningococcal group B vaccine (recombinant, adsorbed) - EMEA/H/C/004051/II/0042
Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege

Ultomiris - ravulizumab - EMEA/H/C/004954/II/0033/G
Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa

Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0107
MCM Vaccine B.V., Rapporteur: Christophe Focke

Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type

b conjugate vaccine (adsorbed) -
EMEA/H/C/003982/II/0109
MCM Vaccine B.V., Rapporteur: Christophe Focke

Zercepac - trastuzumab -
EMEA/H/C/005209/II/0021
Accord Healthcare S.L.U., Rapporteur: Sol Ruiz

WS2298/G
Actraphane-
EMEA/H/C/000427/WS2298/0092/G
Actrapid-
EMEA/H/C/000424/WS2298/0085/G
Actrapid-
EMEA/H/W/005779/WS2298/0001/G
Insulatard-
EMEA/H/C/000441/WS2298/0090/G
Insulatard-
EMEA/H/W/005780/WS2298/0001/G
Levemir-
EMEA/H/C/000528/WS2298/0105/G
Mixtard-
EMEA/H/C/000428/WS2298/0093/G
Protaphane-
EMEA/H/C/000442/WS2298/0089/G
Ryzodeg-
EMEA/H/C/002499/WS2298/0050/G
Tresiba-
EMEA/H/C/002498/WS2298/0057/G
Xultophy-
EMEA/H/C/002647/WS2298/0046/G
Novo Nordisk A/S, Lead Rapporteur: Thalia Marie Estrup Blicher

WS2302/G
Fiasp-
EMEA/H/C/004046/WS2302/0031/G
NovoMix-
EMEA/H/C/000308/WS2302/0112/G
NovoRapid-
EMEA/H/C/000258/WS2302/0142/G
Ryzodeg-
EMEA/H/C/002499/WS2302/0049/G
Novo Nordisk A/S, Lead Rapporteur: Thalia Marie Estrup Blicher

WS2303/G
Saxenda-
EMEA/H/C/003780/WS2303/0033/G
Victoza-
EMEA/H/C/001026/WS2303/0064/G

Xultophy-
EMEA/H/C/002647/WS2303/0045/G
Novo Nordisk A/S, Lead Rapporteur: Johann Lodewijk Hillege

WS2326/G
Hexacima-
EMEA/H/C/002702/WS2326/0138/G
Hexyon-
EMEA/H/C/002796/WS2326/0142/G
Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

COMIRNATY - tozinameran -
EMEA/H/C/005735/II/0145
BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, "To update sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to add recommendations and data for subsequent and booster doses based on real world evidence (RWE) data as well as interim study results from both sub-study E (SSE) and sub-study D (SSD) C4591031 following procedure II/0140 assessment.
The Package Leaflet is updated accordingly."

Cotellic - cobimetinib -
EMEA/H/C/003960/II/0028
Roche Registration GmbH, Rapporteur: Filip Josephson, "Update of section 4.8 of the SmPC in order to add "Pruritus", "Dry skin" and "Oedema peripheral" to the list of adverse drug reactions (ADRs) with frequency "Very common" based on post-marketing experience and the final results from study ML29733; this is an Open-label, single-center, Phase II study evaluating the efficacy and safety of single-agent cobimetinib in patients with histiocytic disorders whose tumours were 1) BRAF V600 wildtype or 2) BRAF V600E mutant and were intolerant to, or unable to access, BRAF inhibitors. The Package Leaflet is updated accordingly."

Flucelvax Tetra - influenza vaccine surface antigen inactivated prepared in cell cultures - EMEA/H/C/004814/II/0030
Seqirus Netherlands B.V., Rapporteur: Sol Ruiz, "Update of section 4.8 of the SmPC in order to add Guillain Barré syndrome (GBS), syncope

and pre-syncope to the list of adverse drug reactions (ADRs) based on the assessment of the global safety database; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the Package Leaflet in order to align it with the information in the SmPC."	
LUTATHERA - lutetium (177Lu) oxodotreotide - EMEA/H/C/004123/II/0038, Orphan Advanced Accelerator Applications, Rapporteur: Janet Koenig, "Update of sections 2, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1, 5.2, 5.3, 6.2, 6.4, 6.5, 6.6, 11 and 12 of the SmPC to align the Lutathera product information to that of the latest Core Data Sheet (CDS) version 2.0. In addition, the MAH is also taking the opportunity to propose additional corrections and changes to align with the QRD template. This application is also used as an opportunity to propose editorial updates to the product information (PI) to improve the language throughout the SmPC and patient leaflet."	
Opsumit - macitentan - EMEA/H/C/002697/II/0047, Orphan Janssen-Cilag International N.V., Rapporteur: Maria Concepcion Prieto Yerro, "Update of section 4.8 of the SmPC in order to add 'flushing' to the list of adverse drug reactions (ADRs) with frequency 'common' based on a cumulative review of cases (post-marketing, clinical studies, registry) and literature; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC."	
Revolade - eltrombopag - EMEA/H/C/001110/II/0070 Novartis Europharm Limited, Rapporteur: Maria Concepcion Prieto Yerro, "Update of section 5.1 of the SmPC based on primary analysis results from study TAPER (CETB115J2411). This is a Phase II, open-label, prospective, single-arm, study to assess ability of eltrombopag to induce sustained remission in subjects with immune thrombocytopenia (ITP) who are refractory or relapsed after first-line steroids. In addition, the MAH took the opportunity to	

implement editorial changes in the SmPC."

Skyrizi - risankizumab - EMEA/H/C/004759/II/0028

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Finbarr Leacy, "Update of section 4.8 of the SmPC in order to add eczema, rash and urticaria to the list of adverse drug reactions (ADRs) based on a thorough evaluation of all events of rash, eczema and urticaria, including clinical trial and post-marketing data from the global safety database; the Package Leaflet is updated accordingly."

Tabrecta - capmatinib - EMEA/H/C/004845/II/0002

Novartis Europharm Limited, Rapporteur: Blanca Garcia-Ochoa, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on hypersensitivity reactions and add hypersensitivity to the list of adverse drug reactions (ADRs) with frequency uncommon, based on cumulative assessment of hypersensitivity cases in studies CINC280A2201, CINC280X1101, CINC280X2102, CINC280A2108, CINC280A2103 (post-DDI phase only), and CINC280A2105 (post-DDI phase only) and MAH global safety database.
The Package Leaflet is updated accordingly."

TRODELVY - sacituzumab govitecan - EMEA/H/C/005182/II/0018/G

Gilead Sciences Ireland UC, Rapporteur: Jan Mueller-Berghaus, "Grouped application comprising two type II variations as follows:
- To update sections 4.8 and 5.2 to address the commitment on providing bioanalytical study reports for antidrug-antibody (ADA) and neutralising antibody (NAb) determination for both studies IMMU- 132-01 and IMMU-132-05, the NAb assay method validation report as well as an integrated summary of immunogenicity.
- To update sections 4.8 and 5.2 to address the commitment to provide data on the impact of concomitant medications including UGT1A1 inhibitors/inducers on SN-38 PK based on the future PopPK model refinement."

WS2368
Invokana-
EMEA/H/C/002649/WS2368/0061

Vokanamet-
EMEA/H/C/002656/WS2368/0066
Janssen-Cilag International N.V., Lead Rapporteur: Martina Weise, "To update section 4.4 of the SmPC in order amend an existing warning on the diabetic ketoacidosis, to indicate that glucosuria may persist longer than expected and that DKA may be prolonged after discontinuation of canagliflozin in some patients based on a cumulative review of literature, MAH global safety database, preclinical and clinical pharmacology data, and clinical study data including cases reports."

B.6.10. CHMP-PRAC assessed procedures

Cablivi - caplacizumab -
EMEA/H/C/004426/II/0040, Orphan
Ablynx NV, Rapporteur: Filip Josephson, PRAC Rapporteur: Jan Neuhauser, "Update of sections 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC in order to update information on long-term efficacy and safety based on final results from study ALX0681-C302/LTS16371 - Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES), listed as a category 3 study in the RMP. The Post-HERCULES study was a Phase III, 36-month follow-up study from HERCULES (parent study) to evaluate the long-term outcomes as well as the safety and efficacy of repeat use of caplacizumab in patients who experienced a recurrence of aTTP.
The RMP version 3.0 has also been submitted."

Ocrevus - ocrelizumab -
EMEA/H/C/004043/II/0034/G
Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Submission of the final report from study BN29739 (VELOCE) listed as a category 3 study in the RMP. This is a phase 3b, multicentre, randomized, parallel-group, open-label study to evaluate the effectiveness of vaccinations in patients with relapsing forms of multiple sclerosis (RMS) undergoing treatment with ocrelizumab.
Submission of the final report from studies MA30005 (CASTING) and MN30035 (CHORDS). These are prospective, multicenter,

international, interventional, open-label phase 3b studies to assess the efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment. The RMP version 8.0 has also been submitted."	
Omnitrope - somatropin - EMEA/H/C/000607/II/0073 Sandoz GmbH, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, "Update of section 4.4 of the SmPC in order to add a new warning on scoliosis following PRAC recommendation from procedure EMEA/H/C/PSUSA/00002772/202003 based on final results from study EP00-401 listed as a category 3 study in the RMP; this is a prospective, open-label, non-comparative, multicenter, Phase IV study to monitor the long-term safety and efficacy of Omnitrope in short children born small for gestational age (SGA), in particular the diabetogenic potential and immunogenicity of rhGH therapy. The Package Leaflet is updated accordingly. The RMP version 12.0 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC."	
Repatha - evolocumab - EMEA/H/C/003766/II/0061 Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Kimmo Jaakkola, "Update of sections 4.8 and 5.1 of the SmPC in order to update safety information and include long-term safety and efficacy data based on final results from study 20130295 and study 20160250 listed as category 3 studies in the RMP; these are phase 3b, multicenter, open-label extension (OLE) studies designed to assess the long-term safety of evolocumab in subjects who completed the FOURIER study (study 20110118). The RMP version 8.0 has also been submitted."	
Sancuso - granisetron - EMEA/H/C/002296/II/0061 Kyowa Kirin Holdings B.V., Rapporteur: Silvijus Abramavicius, PRAC Rapporteur: Rugile Pilviniene, "Update of sections 4.4, 4.6, 4.7, 4.8, 4.10 and 5.3 of the SmPC in order to add 'Serotonin syndrome' and 'Application site	

Reactions' to the list of adverse drug reactions (ADRs) with frequency unknow; as well as 'Application site Irritation' with frequency 'Uncommon' based on post-marketing data and literature. The MAH also proposes to update sections 4.4 and 4.5 of the SmPC to add drug-drug interaction information with buprenorphine/Opioids and serotonergic medicinal products based on post-marketing data and literature.
The Package Leaflet has been updated accordingly. The RMP version 5 has also been submitted. In addition, the MAH took the opportunity to introduce editorial changes in the SmPC."

Xenpozyme - olipudase alfa - EMEA/H/C/004850/II/0001/G, Orphan
Genzyme Europe BV, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, "Grouped application comprising two type II variations as follows:
- To update sections 4.6 of the SmPC in order to include a recommendation to conduct a pregnancy test for women of childbearing potential (WOCP) prior to treatment initiation based on embryo-foetal study in mice (study TER0694). In addition, the MAH proposes an update of section 5.3 of the SmPC based on a re-calculation of exposure margins for the embryo-foetal study. The MAH also proposes to align the SmPC with the updated CCDS.
- To update sections 4.6 and 5.3 of the SmPC in order to include data in lactating mice based on final results from study MSSM-1120 - Evaluation of Olipudase alfa Transfer Into Milk of Lactating Mice.
The Package Leaflet is updated accordingly.
The RMP version 2.0 has also been submitted."

B.6.11. PRAC assessed procedures

PRAC Led
Cervarix - human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) - EMEA/H/C/000721/II/0117
GlaxoSmithkline Biologicals SA, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of the interim report from study EPI-HPV-099 (217743). This is an observational,

retrospective database post-authorisation safety study (PASS) assessing trends and changes over time in incidence of anal cancer and feasibility for a case-control study in European countries that introduced Cervarix in their National Immunisation Programme.
The study was set up to address the missing information on the impact and effectiveness of Cervarix against anal lesions and cancer in the Cervarix RMP. The RMP version 26 has also been submitted."

PRAC Led

Darzalex - daratumumab -
EMEA/H/C/004077/II/0063, Orphan

Janssen-Cilag International N.V., Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, PRAC-CHMP liaison: Bruno Sepodes, "Update of section 4.4 of the SmPC in order to update the warnings and precautions for myocardial infarction and ocular events following PSUSA/00010498/202111, based on the cumulative review of the relevant cases retrieved from the MAH's global safety database, clinical database, epidemiological evaluation and literature review.
The Package Leaflet is updated accordingly."

PRAC Led

Deltyba - delamanid -
EMEA/H/C/002552/II/0061, Orphan

Otsuka Novel Products GmbH, PRAC Rapporteur: Jo Robays, PRAC-CHMP liaison: Christophe Focke, "Update of sections 4.2 and 4.4 of the SmPC in order to update treatment duration based on final results from EU PASS (protocol no. 242-12-402), listed as a category 3 study in the RMP. This is a "A Multicentre, EU-wide, Non-Interventional Post-Authorisation Study to Assess the Safety and Usage of Delamanid in Routine Medical Practice in Multidrug-Resistant Tuberculosis (MDR-TB) Patients". This treatment registry was for monitoring and documenting Deltyba use in routine medical practice and aimed to assess compliance with the recommendations in the authorised product information when prescribed as part of an appropriate combination regimen (ACR) for the treatment of MDR-TB.
The Package Leaflet is updated accordingly. The

RMP version 4.2 has also been submitted. In addition, the MAH took the opportunity to update Annex II section D of the SmPC."

PRAC Led

JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0065

Janssen-Cilag International N.V., PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of an updated RMP version 5.1 in order to update the clinical exposure and risk sections."

PRAC Led

Myozyme - alglucosidase alfa - EMEA/H/C/000636/II/0092

Genzyme Europe BV, RAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Alexandre Moreau, "Update of sections 4.6 and 5.3 of the SmPC in order to update information on pregnancy, lactation and fertility following the request by PRAC in the AR for MEA/024.17 and MEA/025.17 and in PSUSA/00000086/202109; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

PRAC Led

Neulasta - pegfilgrastim - EMEA/H/C/000420/II/0121

Amgen Europe B.V., PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of the final report from PASS study 20170701 listed as a category 3 study in the RMP. This is a cross-sectional survey study to Assess the Effectiveness of the Neulasta Patient Alert Card and to Measure Medication Errors Related to the Use of the Neulasta On-Body Injector. The RMP version 9.0 has also been submitted."

PRAC Led

NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0028

Novavax CZ, a.s., PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of an updated RMP version 2.1 due to reclassification of myocarditis and/or pericarditis from important

potential risk to important identified."

PRAC Led

Saxenda - liraglutide -
EMEA/H/C/003780/II/0034

Novo Nordisk A/S, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of the final report from study NN8022-4246 listed as a category 3 study in the RMP. This is an in-market utilisation non-interventional PASS of liraglutide used for weight management in the UK using the CPRD Primary Care Database. The RMP version 33.0 has also been submitted."

PRAC Led

Synagis - palivizumab -
EMEA/H/C/000257/II/0131

AstraZeneca AB, PRAC Rapporteur: Marie Louise Schougaard Christiansen, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, "Submission of an updated RMP version 2.0 in order to remove from the list of safety concerns "Anaphylaxis, Anaphylactic shock, and Hypersensitivity" and "Medication error of mixing lyophilised and liquid palivizumab before injection". In addition, the MAH took the opportunity to apply the revised template."

PRAC Led

TOBI Podhaler - tobramycin -
EMEA/H/C/002155/II/0053, Orphan

Mylan IRE Healthcare Limited, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of an updated RMP version 8.0 following the request by PRAC in the AR for PSUSA/00009315/202106 in order to update it based on the guidance provided in the GVP and to remove the safety concerns as well as to reflect the finalisation of study CTBM100C2407 and the transfer of ownership."

PRAC Led

Zydelig - idelalisib -
EMEA/H/C/003843/II/0056

Gilead Sciences Ireland UC, Rapporteur: Filip Josephson, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "Submission of the final report from study GS-EU-313-4172 listed as a category 3 study in the RMP. This is a non-interventional study to assess the safety

profile of idelalisib in patients with refractory follicular lymphoma (FL) with primary objective to assess the overall safety profile of idelalisib monotherapy in patients with refractory FL."

PRAC Led
WS2369
Filgrastim Hexal-
EMEA/H/C/000918/WS2369/0066
Zarzio-EMEA/H/C/000917/WS2369/0067
Sandoz GmbH, Lead PRAC Rapporteur: Menno van der Elst, "C.I.11.z - To amend the RMP to reduce the list of safety concerns and remove risks which are well characterised and already included in the product information, following PRAC Assessment Report of PSUR P14 (EMEA/H/C/PSUSA/00001391/202109) dated 05-May-2022. Additionally, the due date of the final study report EP06-501 (MEA007) has been updated.
Furthermore, the MAH took the opportunity to introduce the following editorial changes:
- Removal of pharmaceutical forms and strengths no longer registered in Japan;
- Editorial changes in Part V "Risk minimisation measures"."

B.6.12. CHMP-CAT assessed procedures

Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel -
EMEA/H/C/004731/II/0007/G, ATMP
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Armando Genazzani

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2263
Blitzima-
EMEA/H/C/004723/WS2263/0060
Truxima-
EMEA/H/C/004112/WS2263/0063
Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz

WS2325
Adjupanrix-
EMEA/H/C/001206/WS2325/0080
Ambirix-
EMEA/H/C/000426/WS2325/0123
Bexsero-
EMEA/H/C/002333/WS2325/0116
Cervarix-
EMEA/H/C/000721/WS2325/0116
Fendrix-
EMEA/H/C/000550/WS2325/0080
Infanrix hexa-
EMEA/H/C/000296/WS2325/0319
Menveo-
EMEA/H/C/001095/WS2325/0114
Mosquirix-
EMEA/H/W/002300/WS2325/0063
Rotarix-EMEA/H/C/000639/WS2325/0126
Shingrix-
EMEA/H/C/004336/WS2325/0060
Synflorix-
EMEA/H/C/000973/WS2325/0173
Twinrix Adult-
EMEA/H/C/000112/WS2325/0158
Twinrix Paediatric-
EMEA/H/C/000129/WS2325/0159
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2333
Ambirix-
EMEA/H/C/000426/WS2333/0124
Twinrix Adult-
EMEA/H/C/000112/WS2333/0159
Twinrix Paediatric-
EMEA/H/C/000129/WS2333/0160
GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke

WS2360
HBVAXPRO-
EMEA/H/C/000373/WS2360/0079
Vaxelis-EMEA/H/C/003982/WS2360/0108
Merck Sharp & Dohme B.V., Lead Rapporteur: Jan Mueller-Berghaus

WS2363/G
Copalia-
EMEA/H/C/000774/WS2363/0127/G
Dafiro-
EMEA/H/C/000776/WS2363/0131/G
Exforge-

EMEA/H/C/000716/WS2363/0126/G
Novartis Europharm Limited, Lead Rapporteur:
Thalia Marie Estrup Blicher

WS2370
Nuwiq-EMEA/H/C/002813/WS2370/0051
Vihuma-
EMEA/H/C/004459/WS2370/0033
Octapharma AB, Lead Rapporteur: Jan Mueller-
Berghaus

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures	Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 10-13 October 2022 CHMP plenary:

G.2.2. List of procedures starting in October 2022 for November 2022 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address